Top 170+ Biotech Companies In San Fransisco In 2021
← Visit blog

Top 170+ Biotech Companies In San Fransisco In 2021

Updated on March 10th, 2021

Top 170+ Biotech Companies In San Fransisco In 2021

A hand curated list of 170+ top biotech companies in San Fransisco.
Whether you run a digital agency, a B2B company, or just want to connect with fast growing companies, this is the list for you.
In our premium lists, we also include: • 20+ data points for each company
• Services they’re likely to outsource
• CEO Information & Email
If you’re interested in our premium lists, consider subscribing to our monthly report of tech companies.


Table Of Contents

  1. Orthogonal Diagnostic ($10M to $50M)
  2. Celevity ($1M to $10M)
  3. Aurora Bio ($10M to $50M)
  4. Solstice Biologics ($10M to $50M)
  5. Epiodyne (Less than $1M)
  6. eyeCam ($1M to $10M)
  7. NeuroVia ($1M to $10M)
  8. Clinicai (Less than $1M)
  9. Incode Technologies (Less than $1M)
  10. Mantra Bio ($1M to $10M)
  11. Focal Therapeutics ($50M to $100M)
  12. SyntheX ($1M to $10M)
  13. Serotiny (Less than $1M)
  14. FibroGen ($10M to $50M)
  15. EveryTeam (Less than $1M)
  16. Channel Medsystems ($10M to $50M)
  17. Revitope Oncology (Less than $1M)
  18. Biome Makers ($1M to $10M)
  19. Therini Bio ($10M to $50M)
  20. Engine Biosciences (Less than $1M)
  21. Recardio (Less than $1M)
  22. Altay Therapeutics (Less than $1M)
  23. OneSkin ($1M to $10M)
  24. Glycomine ($1M to $10M)
  25. Spiral Therapeutics (Less than $1M)
  26. Endo Industries (Less than $1M)
  27. ELSI Beauty ($1M to $10M)
  28. BIoEclipse Therapeutics (Less than $1M)
  29. New Lab (Less than $1M)
  30. Culture Biosciences ($1M to $10M)
  31. Everythink ($1M to $10M)
  32. Brightseed ($10M to $50M)
  33. Mission Bio ($10M to $50M)
  34. Xcell Biosciences (Less than $1M)
  35. Alessa Therapeutics ($10M to $50M)
  36. PicnicHealth ($1M to $10M)
  37. Asilomar Bio (Less than $1M)
  38. Delinia ($10M to $50M)
  39. Slope.io ($1M to $10M)
  40. uBiome ($10M to $50M)
  41. Kenzen (Less than $1M)
  42. Auctus Surgical (Less than $1M)
  43. Halo Neuroscience (Less than $1M)
  44. Invuity ($10M to $50M)
  45. SOMOS (Less than $1M)
  46. Nesos ($10M to $50M)
  47. Mitokinin (Less than $1M)
  48. Geom Therapeutics (Less than $1M)
  49. Nirmidas Biotech (Less than $1M)
  50. Pylum Biosciences ($10M to $50M)
  51. Amfora ($10M to $50M)
  52. Katana Pharmaceuticals ($10M to $50M)
  53. Node Labs ($10M to $50M)
  54. Carmot Therapeutics (Less than $1M)
  55. Correlia Biosystems ($1M to $10M)
  56. Cleave Therapeutics ($1M to $10M)
  57. Rio Grande Neurosciences ($10M to $50M)
  58. Vineti ($1M to $10M)
  59. Neuralink ($1M to $10M)
  60. Women's Health Initiative (Less than $1M)
  61. Pheronym (Less than $1M)
  62. System1 Biosciences ($10M to $50M)
  63. Spruce Biosciences ($1M to $10M)
  64. MicroByre (Less than $1M)
  65. Delpor (Less than $1M)
  66. rBIO (Less than $1M)
  67. Audentes Therapeutics ($10M to $50M)
  68. Nurix Therapeutics ($10M to $50M)
  69. LevitasBio ($1M to $10M)
  70. Equator Therapeutics ($1M to $10M)
  71. TRELYS (Less than $1M)
  72. Tenaya Therapeutics ($1M to $10M)
  73. Global Blood Therapeutics ($1M to $10M)
  74. Alector ($10M to $50M)
  75. Singular Bio (Less than $1M)
  76. Holy Grail (Less than $1M)
  77. Benchling ($1M to $10M)
  78. CytoVale (Less than $1M)
  79. Tunitas Therapeutics (Less than $1M)
  80. Cofactor Genomics ($1M to $10M)
  81. Siolta Therapeutics (Less than $1M)
  82. Syapse ($1M to $10M)
  83. Olema Oncology ($1M to $10M)
  84. Perfuse Therapeutics ($10M to $50M)
  85. Wild Type ($1M to $10M)
  86. Denali Therapeutics ($10M to $50M)
  87. Darmiyan ($10M to $50M)
  88. BehavioSec (Less than $1M)
  89. CH4 Global (Less than $1M)
  90. Siluria Technologies ($10M to $50M)
  91. ViewPoint Therapeutics ($1M to $10M)
  92. Neurona Therapeutics ($1M to $10M)
  93. BioQ Pharma ($10M to $50M)
  94. Mekonos Inc. ($1M to $10M)
  95. SillaJen (Less than $1M)
  96. Ovipost (Less than $1M)
  97. Aizon ($1M to $10M)
  98. Fountain Therapeutics ($1M to $10M)
  99. Aeovian Pharmaceuticals ($1M to $10M)
  100. Naked Biome ($1M to $10M)
  101. Pembient (Less than $1M)
  102. Memoir Health (Less than $1M)
  103. Unlearn.AI ($1M to $10M)
  104. PostEra ($1M to $10M)
  105. Dreem ($1M to $10M)
  106. Twist Bioscience ($10M to $50M)
  107. Coral Genomics (Less than $1M)
  108. Zephyr Health ($1M to $10M)
  109. 89bio ($1M to $10M)
  110. Attralus ($10M to $50M)
  111. Enzyme (Less than $1M)
  112. Perlara (Less than $1M)
  113. Delee ($1M to $10M)
  114. OccamzRazor ($1M to $10M)
  115. Gyroscope Innovations (Less than $1M)
  116. Nebula Genomics ($1M to $10M)
  117. Dropprint Genomics ($10M to $50M)
  118. NATURANSA Biotechnology Inc. ($10M to $50M)
  119. Felix Biotechnology (Less than $1M)
  120. Arcturus BioCloud ($1M to $10M)
  121. PipelineRx ($1M to $10M)
  122. Tag.bio (Less than $1M)
  123. Nivien Therapeutics (Less than $1M)
  124. ZBiotics (Less than $1M)
  125. Renewal Mill ($1M to $10M)
  126. Nextbiotics ($10M to $50M)
  127. Oyster Point Pharmaceuticals ($100M to $500M)
  128. Tempest Therapeutics ($1M to $10M)
  129. Endogena Therapeutics (Less than $1M)
  130. Truust Neuroimaging ($10M to $50M)
  131. Ossium Health ($1M to $10M)
  132. Silver Creek Pharmaceuticals (Less than $1M)
  133. TherOptix ($10M to $50M)
  134. Ionetix ($1M to $10M)
  135. Artemys Foods ($10M to $50M)
  136. AmbAgon Therapeutics ($10M to $50M)
  137. IgGenix (Less than $1M)
  138. Aligos Therapeutics ($1M to $10M)
  139. Urhyme (Less than $1M)
  140. Frontier Medicines ($1M to $10M)
  141. Menten AI (Less than $1M)
  142. Cell Design Labs ($1M to $10M)
  143. BioTrillion ($1M to $10M)
  144. ViaeX (Less than $1M)
  145. Qualio ($10M to $50M)
  146. Better Therapeutics ($1M to $10M)
  147. Ivy Natal ($10M to $50M)
  148. Grace Science (Less than $1M)
  149. Profusa ($1M to $10M)
  150. 20n (Less than $1M)
  151. Napo Pharmaceuticals ($1M to $10M)
  152. JointechLabs (Less than $1M)
  153. Actym ($1M to $10M)
  154. Asher Bio ($10M to $50M)
  155. Healthiest You ($10M to $50M)
  156. Datavant ($1M to $10M)
  157. goBalto ($10M to $50M)
  158. MYI Diagnostics (Less than $1M)
  159. Serenus Biotherapeutics ($1M to $10M)
  160. Vir Biotechnology ($1M to $10M)
  161. Shasqi (Less than $1M)
  162. Meissa Vaccines (Less than $1M)
  163. Codiak Biosciences ($10M to $50M)
  164. Brex ($10M to $50M)
  165. BlackThorn Therapeutics ($1M to $10M)
  166. ProLynx ($10M to $50M)
  167. Ranomics ($1M to $10M)
  168. Soley Therapeutics (Less than $1M)
  169. SilviaTerra ($1M to $10M)
  170. Circle Pharma ($1M to $10M)
  171. Enveda Biosciences ($10M to $50M)
  172. Concentric Analgesics (Less than $1M)
  173. Xalud Therapeutics (Less than $1M)
  174. Phylagen ($1M to $10M)
  175. Pendulum Therapeutics (Less than $1M)
  176. Virus Geeks Inc. (Less than $1M)


  1. Orthogonal Diagnostic ($10M to $50M)

    Orthogonal Diagnostic is a San Diego based biotech company that creates innovative medical point-of-care and consumer products. The team is led by David Charlton, known as the father of lateral flow, includes members with over 50 years of combined experience in product development and commercialization. It was founded in 2014 and is headquartered in San Diego, California.

    • $10M to $50M annual revenues
    • 11-50 employees
    • $0.2M raised in January, 2015
    • 1 founder
    • CEO Info & Email: Available in our premium reports 🔐
    • Likely to outsource: Available in our premium reports 🔐

    Visit Website →


  2. rolling armchair beside table


  3. Celevity ($1M to $10M)

    Celevity is a seed-stage company that develops drugs to help dogs live longer, healthier lives. It sees aging as a disease that is able to be slowed and improved with medicines. It was spun out of Laura Deming’s The Longevity Fund. Celevity is headquartered in San Francisco, California.

    • $1M to $10M annual revenues
    • 1-10 employees
    • $4.9M raised in January, 2020
    • 1 founder
    • CEO Info & Email: Available in our premium reports 🔐
    • Likely to outsource: Available in our premium reports 🔐

    Visit Website →


  4. rectangular brown wooden table with chair lot inside building


  5. Aurora Bio ($10M to $50M)

    Aurora Bio is a clinical stage biopharmaceutical company developing a platform of immunotherapies and an imaging diagnostic for multiple systemic amyloid diseases, including AL, ATTR and ALECT2 amyloidosis. The diagnostic imaging agent is currently in Phase 1 with a planned Ph 3 to potentially initiate in 2020. The company also has 2 pre-clinical stage therapeutic programs being developed for a broad range of systemic amyloid diseases. The immunotherapies consist of a peptide-fusion protein as well as cell therapy utilizing engineered macrophages (CAR-M) to remove amyloid. Currently, there are no approved treatments for 29 out of 30 systemic amyloid diseases While approved therapies in ATTR, and those in development for AL an ATTR, target the pre-cursor protein of individual amyloid diseases, Aurora Bio’s goal is to develop immunotherapies that treat across all systemic amyloid diseases.

    • $10M to $50M annual revenues
    • 1-10 employees
    • $0.2M raised in December, 2019
    • 1 founder
    • CEO Info & Email: Available in our premium reports 🔐
    • Likely to outsource: Available in our premium reports 🔐

    Visit Website →


  6. three women sitting around table using laptops


  7. Solstice Biologics ($10M to $50M)

    Solstice Biologics is a biotech company that provides solutions for targeting and delivering nucleic acid therapeutics. The Company specializes in the development of small, cell-permeable RNAi pro-drugs that can enter many different cell types and deliver on the promise of RNAi therapeutics. It was established in 2012 and is based in San Francisco, California.

    • $10M to $50M annual revenues
    • 11-50 employees
    • $4M raised in December, 2015
    • 1 founder
    • CEO Info & Email: Available in our premium reports 🔐
    • Likely to outsource: Available in our premium reports 🔐

    Visit Website →


  8. brown and white table and chairs


  9. Epiodyne (Less than $1M)

    Epiodyne is a biotechnology company based in San Francisco, California.

    • Less than $1M annual revenues
    • 1-10 employees
    • $5.8M raised in October, 2017
    • 1 founder
    • CEO Info & Email: Available in our premium reports 🔐
    • Likely to outsource: Available in our premium reports 🔐

    Visit Website →


  10. grey wooden table and black leather rolling chairs


  11. eyeCam ($1M to $10M)

    eyeCam is design and manufacturing company that specializes in wearable computing devices. The company develops a wearable video communications system as well as a human interfacing and computing device. The company was founded by Bryan Davis in 2014 and is headquartered in San Francisco, California.

    • $1M to $10M annual revenues
    • 11-50 employees
    • $6M raised in November, 2017
    • 1 founder
    • CEO Info & Email: Available in our premium reports 🔐
    • Likely to outsource: Available in our premium reports 🔐

    Visit Website →


  12. tennis table in room


  13. NeuroVia ($1M to $10M)

    NeuroVia, Inc. is committed to addressing unmet medical needs in neurological diseases with the primary goal to arrest the onset of devastating neurological deficits associated with X-ALD.

    • $1M to $10M annual revenues
    • 51-100 employees
    • $14M raised in July, 2017
    • 1 founder
    • CEO Info & Email: Available in our premium reports 🔐
    • Likely to outsource: Available in our premium reports 🔐

    Visit Website →


  14. rectangular brown wooden table


  15. Clinicai (Less than $1M)

    Clinicai is building a smart toilet monitor for non-invasive early detection of gastrointestinal cancers and diseases.

    • Less than $1M annual revenues
    • 1-10 employees
    • $0.1M raised in December, 2018
    • 4 founders
    • CEO Info & Email: Available in our premium reports 🔐
    • Likely to outsource: Available in our premium reports 🔐

    Visit Website →


  16. grayscale photo of people in room


  17. Incode Technologies (Less than $1M)

    Incode Technologies is a digital identity company that builds delightful and secure biometric identity products for frictionless banking, payment, hospitality, and retail experiences. Incode is recognized as a leader in enterprise-grade facial recognition by the US Government. Built for the next generation of consumers, Incode’s products are already used by some of the world’s largest banks, financial institutions, governments, and retailers. Incode sets a new standard in convenience and security for those who matter the most: the end-users. Incode was founded in 2015 by a passionate serial-entrepreneur and a group of hard-working, goal-crushing individuals. Headquartered in San Francisco, Incode operates globally with additional offices in Europe and Latin America.

    • Less than $1M annual revenues
    • 11-50 employees
    • $10M raised in October, 2019
    • 1 founder
    • CEO Info & Email: Available in our premium reports 🔐
    • Likely to outsource: Available in our premium reports 🔐

    Visit Website →


  18. two men using computers


  19. Mantra Bio ($1M to $10M)

    Mantra Bio develops a novel next-generation, targeted therapeutics based on its proprietary platform for engineering Targeted Exosome Vehicles (TEVs). The Company's REVEAL platform, which integrates computational and wet biology, and automation, leverages the diversity of exosomes to enable the rational design of therapeutics directed at a wide range of tissue and cellular targets. Mantra Bio has also established a scalable biomanufacturing process and related technologies to ensure this new class of therapeutics is reproducibly made at high purity.

    • $1M to $10M annual revenues
    • 11-50 employees
    • $25M raised in July, 2020
    • 3 founders
    • CEO Info & Email: Available in our premium reports 🔐
    • Likely to outsource: Available in our premium reports 🔐

    Visit Website →


  20. group of people sitting beside rectangular wooden table with laptops


  21. Focal Therapeutics ($50M to $100M)

    Focal Therapeutics is a medical device company that was established to help surgeons, radiation oncologists, and other clinicians to clearly identify a surgical site through the use of an innovative tissue marker. The company’s BioZorb™ tissue marker is an implantable device placed by surgeons that delineates the site of tissue removal in three dimensions. BioZorb is applicable to virtually all forms of radiation therapy and assists physicians in treatment planning, patient positioning during treatment, and long-term follow-up. Focal Therapeutics’ leadership team has a long track record in the development and commercialization of medical devices, particularly in the field of breast cancer care. As such, the company has chosen to offer BioZorb initially to surgeons and radiation oncologists who treat breast cancer patients.

    • $50M to $100M annual revenues
    • 11-50 employees
    • $3.8M raised in March, 2016
    • 1 founder
    • CEO Info & Email: Available in our premium reports 🔐
    • Likely to outsource: Available in our premium reports 🔐

    Visit Website →




  22. SyntheX ($1M to $10M)

    SyntheX created a novel cell-based, synthetic biology-driven drug selection platform, that allows for the efficient synthesis and identification of peptides and macrocycles that selectively disrupt intracellular protein-protein interactions of interest. Although the platform has broad application, the initial focus is on oncology. Targets are selected based on the concepts of synthetic lethality and oncogene addiction, with the first program focused on DNA damage repair and working through a novel cell death mechanism that was uncovered.

    • $1M to $10M annual revenues
    • 11-50 employees
    • $6.2M raised in March, 2017
    • 2 founders
    • CEO Info & Email: Available in our premium reports 🔐
    • Likely to outsource: Available in our premium reports 🔐

    Visit Website →


  23. man in black jacket sitting on chair


  24. Serotiny (Less than $1M)

    Serotiny partners with leaders in the life sciences to make better therapies and tools by designing multi-domain proteins with novel functionality. They tailor protein designs for unique demands including treatment of cancers and genetic disorders.

    • Less than $1M annual revenues
    • 1-10 employees
    • $3M raised in July, 2018
    • 2 founders
    • CEO Info & Email: Available in our premium reports 🔐
    • Likely to outsource: Available in our premium reports 🔐

    Visit Website →


  25. selective focus photography of desk lamp on table


  26. FibroGen ($10M to $50M)

    FibroGen is a research-based biotechnology company using its expertise in connective tissue growth factor (CTGF) and hypoxia-inducible factor (HIF) biology to discover, develop, and commercialize novel therapeutics for serious unmet medical needs. The company applies its pioneering expertise in hypoxia-inducible factor (HIF), connective tissue growth factor (CTGF) biology, and clinical development to advance innovative medicines for the treatment of anemia, fibrotic disease, and cancer. FibroGen's product Roxadustat is an oral small-molecule inhibitor of HIF prolyl hydroxylase activity in worldwide Phase 3 clinical development for the treatment of anemia in chronic kidney disease (CKD), with a New Drug Application currently under review in China by the State Drug Administration or SDA (formerly the China Food and Drug Administration).

    • $10M to $50M annual revenues
    • 251-500 employees
    • $62M raised in July, 2016
    • 1 founder
    • CEO Info & Email: Available in our premium reports 🔐
    • Likely to outsource: Available in our premium reports 🔐

    Visit Website →


  27. people using desktop computer inside office


  28. EveryTeam (Less than $1M)

    At EveryTeam, we believe it's time to rebuild the way teams organize shared content. We're focusing on the same principles that made GitHub the go-to collaborative workspace for engineering teams, with a repository that extends to every team's content. Our product creates trust and accountability within every team by helping teams know what’s important and find what’s relevant, increasing trust and reliability in both their shared content and in their team.

    • Less than $1M annual revenues
    • 1-10 employees
    • $3M raised in June, 2018
    • 1 founder
    • CEO Info & Email: Available in our premium reports 🔐
    • Likely to outsource: Available in our premium reports 🔐

    Visit Website →


  29. architectural photo of buildings during daytime


  30. Channel Medsystems ($10M to $50M)

    Channel Medystems is a clinical-stage medical technology engaged in the development of proprietary cryo-ablation delivery technologies. The company is developing proprietary cryo-ablation delivery technologies. They strive to develop treatments to meet the unique needs of female patients and the high standards of their healthcare providers. Channel Medsystems was founded in 2009 and headquartered in San Francisco, California.

    • $10M to $50M annual revenues
    • 11-50 employees
    • $14.1M raised in August, 2017
    • 1 founder
    • CEO Info & Email: Available in our premium reports 🔐
    • Likely to outsource: Available in our premium reports 🔐

    Visit Website →


  31. people sitting in front of computer monitors


  32. Revitope Oncology (Less than $1M)

    Revitope is developing a novel approach to cancer immunotherapy. Cancer patients typically have strong cytotoxic immunity against viral pathogens while lacking immunity against their tumors. Revitope’s technology redirects an exisiting viral immune response to treat cancer. Revitope’s antibody peptide epitope complex (APEC) technology selectively delivers an immunodominant viral peptide to the tumor cell, thereby activating exisiting T cells that recognize the tumor as virally infected, and kill it.

    • Less than $1M annual revenues
    • 1-10 employees
    • $8.5M raised in February, 2016
    • 2 founders
    • CEO Info & Email: Available in our premium reports 🔐
    • Likely to outsource: Available in our premium reports 🔐

    Visit Website →


  33. people standiunmg


  34. Biome Makers ($1M to $10M)

    Biome Makers is a biotech company born in Silicon Valley specialized in the identification and understanding of the microbiome. They use DNA Sequencing technologies and proprietary Intelligent Computing systems to ease detailed information and recommendations that allow customers improve their agricultural production and the quality of their products.

    • $1M to $10M annual revenues
    • 1-10 employees
    • $2M raised in March, 2020
    • 2 founders
    • CEO Info & Email: Available in our premium reports 🔐
    • Likely to outsource: Available in our premium reports 🔐

    Visit Website →


  35. people sitting on chairs near tables during daytime


  36. Therini Bio ($10M to $50M)

    Therini Bio is dedicated to the research and development of novel therapeutics for the treatment of neurological diseases. The company's approach is based on novel findings by the Akassoglou lab at Gladstone/UCSF that implicate fibrin as a key driver of neuroinflammation.

    • $10M to $50M annual revenues
    • 1-10 employees
    • $6.5M raised in July, 2019
    • 1 founder
    • CEO Info & Email: Available in our premium reports 🔐
    • Likely to outsource: Available in our premium reports 🔐

    Visit Website →


  37. two women sitting beside table using MacBooks


  38. Engine Biosciences (Less than $1M)

    Engine Biosciences is a biotech company that applies machine learning to genomics for drug discovery. Engine Biosciences is a venture-backed San Francisco- and Asia-based technology company pioneering network biomedicine. The company's proprietary and patented technologies oriented around deciphering the complexity of biology networks include both high-throughput wet lab experimentation and artificial intelligence algorithms for drug discovery and cellular reprogramming. This platform, developed through several years of research by our scientific founding and leadership team who include faculty members at MIT, Harvard, Mayo Clinic, and UCSD, dramatically accelerates and reduces costs of the R&D process for new medical therapies. We are actively applying the platform internally and with partners across a range of disease indications.

    • Less than $1M annual revenues
    • 1-10 employees
    • $10M raised in January, 2018
    • 3 founders
    • CEO Info & Email: Available in our premium reports 🔐
    • Likely to outsource: Available in our premium reports 🔐

    Visit Website →


  39. man and woman sitting at table


  40. Recardio (Less than $1M)

    Recardio is a biotechnology company based in San Francisco, California.

    • Less than $1M annual revenues
    • 51-100 employees
    • $3M raised in November, 2015
    • 1 founder
    • CEO Info & Email: Available in our premium reports 🔐
    • Likely to outsource: Available in our premium reports 🔐

    Visit Website →


  41. men sitting of chair inside room


  42. Altay Therapeutics (Less than $1M)

    Altay Therapeutics is a biotech company focused on finding and discovering small molecule therapies for chronic inflammatory conditions. It is currently focused on finding curative therapies for fibrosis, NASH, and liver cancer. It develops novel small molecule drugs against transcriptional regulators that are validated drivers of disease. It was founded in 2019 and is headquartered in San Francisco, California.

    • Less than $1M annual revenues
    • 1-10 employees
    • $0.2M raised in March, 2020
    • 1 founder
    • CEO Info & Email: Available in our premium reports 🔐
    • Likely to outsource: Available in our premium reports 🔐

    Visit Website →


  43. brown wooden table and chairs


  44. OneSkin ($1M to $10M)

    OnSkin designs anti-aging molecules that fights with skin aging. Its anti-aging molecules uses animal-free 3D human skin and genomic data to find molecules able to truly reverse skin aging and also combines real 3D human skin models and molecular markers to discover and produce the first generation of molecules for personalized anti-aging skincare products, enabling individuals to recover skin ageing and prevent skin diseases.

    • $1M to $10M annual revenues
    • 1-10 employees
    • $2M raised in May, 2017
    • 4 founders
    • CEO Info & Email: Available in our premium reports 🔐
    • Likely to outsource: Available in our premium reports 🔐

    Visit Website →


  45. people having meeting on rectangular brown table


  46. Glycomine ($1M to $10M)

    There are approximately 7,000 rare disorders worldwide. Each day more are being discovered. 95% of rare diseases have not one single FDA approved treatment. Glycomine develops therapeutics for diseases which have no treatment options.

    • $1M to $10M annual revenues
    • 1-10 employees
    • $33M raised in August, 2019
    • 1 founder
    • CEO Info & Email: Available in our premium reports 🔐
    • Likely to outsource: Available in our premium reports 🔐

    Visit Website →


  47. people sitting beside rectangular brown table with laptops


  48. Spiral Therapeutics (Less than $1M)

    Spiral Therapeutics is a clinical stage pharmaceutical company delivering novel therapies for hearing loss. Through the use proprietary therapeutics and drug delivery technologies, Spiral is building a pipeline of advanced therapies in a field with large unmet needs and no approved therapies. Spiral’s lead candidate, LPT99, reached the clinic in December 2018. Spiral was launched in early 2016 and is headquartered in Brisbane, CA.

    • Less than $1M annual revenues
    • 11-50 employees
    • $5.6M raised in December, 2018
    • 1 founder
    • CEO Info & Email: Available in our premium reports 🔐
    • Likely to outsource: Available in our premium reports 🔐

    Visit Website →


  49. photo of industrial machines near table


  50. Endo Industries (Less than $1M)

    Endo Industries is an agricultural biotech-focused company designing and producing the healthiest medicinal starter plants.

    • Less than $1M annual revenues
    • 1-10 employees
    • $0.1M raised in November, 2019
    • 1 founder
    • CEO Info & Email: Available in our premium reports 🔐
    • Likely to outsource: Available in our premium reports 🔐

    Visit Website →


  51. people sitting on black chairs


  52. ELSI Beauty ($1M to $10M)

    Based upon 10 years of skin research and industrial experience with renowned French and US institutions, ELSI was created to disrupt the $120 billion health and beauty industry, by giving consumers a new array of science-backed and clean beauty products powered by advanced analytics.

    • $1M to $10M annual revenues
    • 1-10 employees
    • $1M raised in October, 2019
    • 1 founder
    • CEO Info & Email: Available in our premium reports 🔐
    • Likely to outsource: Available in our premium reports 🔐

    Visit Website →


  53. man in gray sweatshirt sitting on chair in front of iMac


  54. BIoEclipse Therapeutics (Less than $1M)

    BioEclipse Therapeutics is a clinical-stage oncology company that develops immuno-oncology therapeutics using its proprietary technology. Its mission is to improve clinical outcomes and the quality of life for all cancer patients and to be at the forefront of turning cancer into a curable disease. The company has harnessed a refined understanding of the human immune system, gaining insights into the reasons the body’s defense system so often turns a blind eye to the presence of cancerous cells and tumors. In response, BioEclipse Therapeutics pairs activated immune cells with an adapted oncolytic virus that selectively infects and kills malignant cells.

    • Less than $1M annual revenues
    • 1-10 employees
    • $7.7M raised in June, 2019
    • 3 founders
    • CEO Info & Email: Available in our premium reports 🔐
    • Likely to outsource: Available in our premium reports 🔐

    Visit Website →


  55. men using computers


  56. New Lab (Less than $1M)

    We are committed to full automation and robotics of industry of laboratory studies, making it more accessible to public. In 2015, we started construction of the first laboratory of such a kind with its own software technologies, which has no analogues in the world. “New Lab” laboratory is located in Silicon Valley, California.

    • Less than $1M annual revenues
    • 11-50 employees
    • $2M raised in November, 2015
    • 2 founders
    • CEO Info & Email: Available in our premium reports 🔐
    • Likely to outsource: Available in our premium reports 🔐

    Visit Website →




  57. Culture Biosciences ($1M to $10M)

    Culture Biosciences develops automated bio-reactor that helps biotech companies optimize their manufacturing processes and brings products to market faster. The company also builds automated tools for fermentation. It has a digital bio-manufacturing platform to enable scientists to run, monitor, and analyze bio-reactors faster than traditional approaches by robotic sample handling and cloud data monitoring and analysis. Culture Biosciences was founded in 2016 and is headquartered in San Francisco, California.

    • $1M to $10M annual revenues
    • 11-50 employees
    • $15M raised in March, 2020
    • 2 founders
    • CEO Info & Email: Available in our premium reports 🔐
    • Likely to outsource: Available in our premium reports 🔐

    Visit Website →


  58. people sitting and using laptops


  59. Everythink ($1M to $10M)

    Build Smart Geolocated Puppets, manage real-time data and connect needs with solutions through people, groups of people, automated processes and devices. Now you can empower your company, automate processes and measure the performance of each actor of your business in real time. Everythink is a new tool for organizations that seek to adapt to future work trends and emerging lifestyles by improving internal and external communication and integrating relationships among their members and to automate their processes and attack their weaknesses in real-time. Technologies Everythink uses include: Virtual/Augmented Reality: geolocated Intelligent Assistants with different capacities to maintain users connected, obtain real-time information, event generation and the ability to execute/create automated processes. Blockchain: storage of data obtained in each Intelligent Assistant. Machine Learning: the Intelligent Assistant is going to learn to behave with each type of user depending on the interactions it makes with each of them. Data Science: analysis of data obtained by the intelligent assistants with suggestions of new data sets by verified professionals. Industries/Areas Everythink are transforming: Healthcare, Education, Human Resources, Real Estate, Legal Tech, Government, Networks, and much more. In less than 24 hours you can build your Geolocated Intelligent Assistants, without coding. They can manage data and connect needs with solutions interconnecting people, groups of people, automated processes and objects in real-time. What are you waiting for? https://everythink.ai/

    • $1M to $10M annual revenues
    • 11-50 employees
    • $0.1M raised in April, 2019
    • 2 founders
    • CEO Info & Email: Available in our premium reports 🔐
    • Likely to outsource: Available in our premium reports 🔐

    Visit Website →


  60. rolling armchair beside table


  61. Brightseed ($10M to $50M)

    Brightseed is a biotechnology company that features artificial intelligence that reveals powerful compounds hidden in nature. The company enables a healthier future by illuminating and activating the connections between people and plants. It was founded in 2017 and headquartered in San Francisco, California.

    • $10M to $50M annual revenues
    • 11-50 employees
    • $27M raised in September, 2020
    • 3 founders
    • CEO Info & Email: Available in our premium reports 🔐
    • Likely to outsource: Available in our premium reports 🔐

    Visit Website →


  62. rectangular brown wooden table with chair lot inside building


  63. Mission Bio ($10M to $50M)

    Mission Bio delivers targeted solutions for high-impact applications with the Tapestri Platform. The Tapestri Platform is the industry’s first and only single-cell multi-omics platform, enabling genotype and phenotype from the same cell and precise detection of heterogeneity in disease progression and treatment response. Application areas include oncology blood cancers, solid tumors, and genome editing validation.

    • $10M to $50M annual revenues
    • 51-100 employees
    • $70M raised in August, 2020
    • 4 founders
    • CEO Info & Email: Available in our premium reports 🔐
    • Likely to outsource: Available in our premium reports 🔐

    Visit Website →


  64. three women sitting around table using laptops


  65. Xcell Biosciences (Less than $1M)

    Xcell Biosciences is a San Francisco-based life science start-up company that is developing novel and disruptive systems for cell therapy development and production. Our proprietary technology enables fine control of primary cell phenotype and function, enabling an entirely new capability for optimizing efficacy and persistence of immune cell therapies.

    • Less than $1M annual revenues
    • 11-50 employees
    • $12M raised in February, 2017
    • 3 founders
    • CEO Info & Email: Available in our premium reports 🔐
    • Likely to outsource: Available in our premium reports 🔐

    Visit Website →


  66. brown and white table and chairs


  67. Alessa Therapeutics ($10M to $50M)

    Alessa Therapeutics is a pre-clinical stage company that develops localized treatments for solid organ disease.

    • $10M to $50M annual revenues
    • 1-10 employees
    • $3M raised in March, 2019
    • 2 founders
    • CEO Info & Email: Available in our premium reports 🔐
    • Likely to outsource: Available in our premium reports 🔐

    Visit Website →


  68. grey wooden table and black leather rolling chairs


  69. PicnicHealth ($1M to $10M)

    PicnicHealth is all about making medical records easy to access and using data to power the next frontier of medical research. We’re led by the belief that there’s power in medical information when it’s used well, and that every person has a right to their own theirs. And we've built award-winning machine learning to do it. How? PicnicHealth works directly with patients to give them the only tool anywhere that truly provides all of their medical records from any doctor or healthcare system in the US—in an easy-to-use, secure online dashboard. Not only that, but patients can choose to contribute their data to scientific research, which helps life sciences researchers accelerate breakthroughs in care. Researchers use this anonymized “real-world data” to understand how diseases are experienced by patients and treated by clinicians in the real world, going beyond the highly controlled setting of clinical trials. The goal is to create better treatments that can ultimately improve outcomes for patients. Whether you’re a scientist, engineer, or patient yourself, we’re looking for passionate people to join us in redefining an industry during our next stage of growth. To date we’ve helped tens of thousands of patients, partnered with some of the world’s largest biopharma companies, and raised more than $35M from Felicis Ventures, Amplify Partners, Foresite Capital, Refactor Capital, and Y Combinator.

    • $1M to $10M annual revenues
    • 51-100 employees
    • $25M raised in September, 2020
    • 2 founders
    • CEO Info & Email: Available in our premium reports 🔐
    • Likely to outsource: Available in our premium reports 🔐

    Visit Website →


  70. tennis table in room


  71. Asilomar Bio (Less than $1M)

    Asilomar Bio is creating crop protection tools to enhance harvest yields and efficiency by leveraging their breakthrough technology in plant science and chemical manufacturing.

    • Less than $1M annual revenues
    • 1-10 employees
    • $12.3M raised in December, 2017
    • 2 founders
    • CEO Info & Email: Available in our premium reports 🔐
    • Likely to outsource: Available in our premium reports 🔐

    Visit Website →


  72. rectangular brown wooden table


  73. Delinia ($10M to $50M)

    Delinia was founded to discover and develop novel therapeutics for the treatment of autoimmune and inflammatory diseases. Delinia’s lead program is a molecule that selectively potentiates and expands regulatory T cells (Tregs), the powerful immune cells that are critical to maintaining self-tolerance and immune system homeostasis. Delinia’s scientific founders and experienced executive leaders are working to advance the company’s initial programs to the clinic.

    • $10M to $50M annual revenues
    • 11-50 employees
    • $35M raised in September, 2016
    • 1 founder
    • CEO Info & Email: Available in our premium reports 🔐
    • Likely to outsource: Available in our premium reports 🔐

    Visit Website →


  74. grayscale photo of people in room


  75. Slope.io ($1M to $10M)

    Slope connects a clinical trial to its supply chain, coordinating the operational complexity of getting devices, drugs, & kits from suppliers to sites to patients in real-time with complete traceability.

    • $1M to $10M annual revenues
    • 1-10 employees
    • $0.9M raised in February, 2017
    • 2 founders
    • CEO Info & Email: Available in our premium reports 🔐
    • Likely to outsource: Available in our premium reports 🔐

    Visit Website →


  76. two men using computers


  77. uBiome ($10M to $50M)

    uBiome is a citizen science startup that sequences the human microbiome. As the first and largest successful crowdsourced citizen science project in history, we allow the public access to cutting edge sequencing technology and are building a data platform to gather, analyze, and translate data about the human microbiome. We have developed the first sequencing-based, clinical microbiome tests and are committed to empowering patients and their healthcare providers to understand and take greater control of their health. We provide actionable insights and information to help foster understanding about the microbiome and the role it plays in health and wellness. union's mission is to transform research into useful products based on the microbiome. uBiome is the world’s first effort to map the human microbiome with citizen science. While the sequencing of the human genome has provided invaluable knowledge, it is very difficult to change their own genetic makeup. The microbiome, in contrast, is much more easily changed through simple means such as healthful probiotic cultures and other lifestyle interventions. The microbiome thus may provide some of the most important medical breakthroughs of their era. uBiome will ultimately empower participants to manage their microbiomes to improve their health as well as make important scientific discoveries for humanity.

    • $10M to $50M annual revenues
    • 101-250 employees
    • $83M raised in September, 2018
    • 2 founders
    • CEO Info & Email: Available in our premium reports 🔐
    • Likely to outsource: Available in our premium reports 🔐

    Visit Website →


  78. group of people sitting beside rectangular wooden table with laptops


  79. Kenzen (Less than $1M)

    Kenzen creates personal health wearables to support its users in all dimensions of health, including wellness, activities, 3D motion, and performance. The company provides its clients with a variety of personal health monitors that report data in real time to smartphone devices. Through its data, Kenzen aims to enable individuals to make critical decisions in training and competitions. Its primary product, Kenzen ECHO, is a small, flexible patch that helps its users understand their physiology, and get personalized health insights and notifications to help improve performance, recovery, and prevent injury. Kenzen was founded in 2014 by Sonia Sousa and Steve Pecko. It is based in San Francisco, California.

    • Less than $1M annual revenues
    • 1-10 employees
    • $1M raised in January, 2021
    • 2 founders
    • CEO Info & Email: Available in our premium reports 🔐
    • Likely to outsource: Available in our premium reports 🔐

    Visit Website →




  80. Auctus Surgical (Less than $1M)

    Auctus Surgical is developing a dynamic Vertebral Body tethering system for the treatment of pediatric scoliosis. The Auctus system is a non-fusion, endoscopic system allowing for non-surgical adjustment over time. Auctus has also licensed technology relating to magnetically adjustable growing rods for use in pediatric scoliosis and limb lengthening.

    • Less than $1M annual revenues
    • 1-10 employees
    • $0.1M raised in May, 2019
    • 1 founder
    • CEO Info & Email: Available in our premium reports 🔐
    • Likely to outsource: Available in our premium reports 🔐

    Visit Website →


  81. man in black jacket sitting on chair


  82. Halo Neuroscience (Less than $1M)

    Halo Neuroscience develops and markets neurotechnology systems to help individuals unlock their true potential. Their first product, Halo Sport, utilizes Neuropriming technology to accelerate skill and strength acquisition in elite athletes. Neuropriming is the process of using electrical stimulation during movement-based training to build stronger, more optimized connections between your brain and muscles. This process induces a temporary state of hyper-learning or "hyperplasticity" in the brain, which refines the brain's ability to learn and adapt to training. The company was incorporated in 2013 and is based in San Francisco, CA.

    • Less than $1M annual revenues
    • 11-50 employees
    • $1M raised in April, 2018
    • 4 founders
    • CEO Info & Email: Available in our premium reports 🔐
    • Likely to outsource: Available in our premium reports 🔐

    Visit Website →


  83. selective focus photography of desk lamp on table


  84. Invuity ($10M to $50M)

    Invuity, Inc. develops visualization products for the less invasive surgical field applications. It offers BriteField Port System that provides illumination and visualization during minimally invasive procedures; and BriteField McCulloch retractor, which allows physicians to achieve visualization during surgery while using traditional techniques. Invuity, Inc. was formerly known as Spotlight Surgical Inc. The company was founded in 2004 and is headquartered in San Francisco, California.

    • $10M to $50M annual revenues
    • 51-100 employees
    • $22.9M raised in February, 2015
    • 2 founders
    • CEO Info & Email: Available in our premium reports 🔐
    • Likely to outsource: Available in our premium reports 🔐

    Visit Website →


  85. people using desktop computer inside office


  86. SOMOS (Less than $1M)

    Somos is a Mexican company of genetic solutions that offers you evidence of global ancestry and Latin American ancestry with an important differentiator: ancestry of Latin American groups, which makes it the first test to offer this kind of information.

    • Less than $1M annual revenues
    • 1-10 employees
    • $0.1M raised in October, 2020
    • 1 founder
    • CEO Info & Email: Available in our premium reports 🔐
    • Likely to outsource: Available in our premium reports 🔐

    Visit Website →


  87. architectural photo of buildings during daytime


  88. Nesos ($10M to $50M)

    Nēsos develops and commercializes electrical field treatments for neurological disorders. It is critically supported by expert clinical and scientific collaborators from leading academic institutions, including Stanford, Vall d'Hebron, Harvard, Mount Sinai, Feinstein Institute, University Of California, San Diego (UCSD), and the University Of California, San Francisco (UCSF). It was co-founded by Konstantinos Alataris and other neuroscientists.

    • $10M to $50M annual revenues
    • 11-50 employees
    • $16.5M raised in December, 2020
    • 1 founder
    • CEO Info & Email: Available in our premium reports 🔐
    • Likely to outsource: Available in our premium reports 🔐

    Visit Website →


  89. people sitting in front of computer monitors


  90. Mitokinin (Less than $1M)

    Mitokinin is operates in the healthcare industry focusing on biotechnology business. It launches medicinal chemistry effort to generate kinetin analogs optimized for activating PINK1. It plans to develop the analog or optimized variants to treat Parkinson's disease.

    • Less than $1M annual revenues
    • 11-50 employees
    • $5M raised in October, 2018
    • 1 founder
    • CEO Info & Email: Available in our premium reports 🔐
    • Likely to outsource: Available in our premium reports 🔐

    Visit Website →


  91. people standiunmg


  92. Geom Therapeutics (Less than $1M)

    Geom Therapeutics is a biotechnology company focused on the development of novel antibiotics for multidrug-resistant Gram-negative infections. Geom is a joint venture with LegoChem Biosciences, a publicly traded Korean biotechnology company (KOSDAQ:141080) and the inventor of GT-1. GT-1, their lead product candidate, a cephalosporin with a novel uptake mechanism, has demonstrated broad spectrum efficacy against Gram-negative pathogens. They are developing GT-1 for serious bacterial infections, including those caused by MDR P. aeruginosa and Acinetobacter spp. They have built an exceptional research and development team with deep expertise in the development of new antibiotics from discovery through approval. Their mission is to improve patients’ lives by developing novel antibiotics to treat resistant infections for which there are no available therapies.

    • Less than $1M annual revenues
    • 1-10 employees
    • $4.4M raised in April, 2017
    • 1 founder
    • CEO Info & Email: Available in our premium reports 🔐
    • Likely to outsource: Available in our premium reports 🔐

    Visit Website →


  93. people sitting on chairs near tables during daytime


  94. Nirmidas Biotech (Less than $1M)

    Nirmidas provides innovative solutions to life science and healthcare technological problems and aims to improve human life quality for the world. Nirmidas develops, manufactures, and markets breakthrough biological testing, assay and imaging technologies, based on a novel red to near infrared fluorescence enhancing detection platform. We aim to develop personal and portable diagnostics systems for early disease diagnosis and prognosis monitoring, as well as for population-based screening. Our products lie at the intersection of life science research, in vitro diagnosis and digital healthcare.

    • Less than $1M annual revenues
    • 1-10 employees
    • $5M raised in February, 2016
    • 2 founders
    • CEO Info & Email: Available in our premium reports 🔐
    • Likely to outsource: Available in our premium reports 🔐

    Visit Website →


  95. two women sitting beside table using MacBooks


  96. Pylum Biosciences ($10M to $50M)

    Pylum Biosicences offers an Avidocin platform technology capable of generating bactericidal protein complexes targeting specific bacterial pathogens. The Avidocin platform can be quickly modified to generate new protein complexes to kill emerging strains as their genome sequences become available. Avidocin proteins employ a unique killing mechanism that is oblivious to the mechanisms bacteria have evolved to resist traditional antibiotics, and because of their tailorable specificity, they can be directed against specific species or strains with minimal or no off-target effects. The company currently has in development Avidocin agents targeting 10 different organisms including threatening human pathogens such as C. difficile, uropathogenic E. coli, and K. pneumonia. Pre-clinical animal studies have demonstrated that Avidocin proteins can be orally or parentally administered to prevent or treat disease with impressive efficacy in multiple infection models.

    • $10M to $50M annual revenues
    • 1-10 employees
    • $1M raised in February, 2020
    • 3 founders
    • CEO Info & Email: Available in our premium reports 🔐
    • Likely to outsource: Available in our premium reports 🔐

    Visit Website →


  97. man and woman sitting at table


  98. Amfora ($10M to $50M)

    Amfora is an emerging leader in the use of biotechnology to address the rapidly growing global demand for protein. Amfora is working to develop nutritionally enhanced forage crops for a market expected to have an annual value of as much as $12 billion a year. The company is based in San Francisco, California and is a portfolio company of Spruce Capital Partners LLC/MLS II Fund.

    • $10M to $50M annual revenues
    • 1-10 employees
    • $7.3M raised in February, 2021
    • 1 founder
    • CEO Info & Email: Available in our premium reports 🔐
    • Likely to outsource: Available in our premium reports 🔐

    Visit Website →


  99. men sitting of chair inside room


  100. Katana Pharmaceuticals ($10M to $50M)

    Katana Pharmaceuticals is a biotech company developing novel treatments for neonatal patient populations and rare pediatric disorders.

    • $10M to $50M annual revenues
    • 11-50 employees
    • $1.1M raised in June, 2020
    • 2 founders
    • CEO Info & Email: Available in our premium reports 🔐
    • Likely to outsource: Available in our premium reports 🔐

    Visit Website →


  101. brown wooden table and chairs


  102. Node Labs ($10M to $50M)

    Node Labs is a biotechnology company based in San Francisco, California.

    • $10M to $50M annual revenues
    • 1-10 employees
    • $0.4M raised in May, 2018
    • 2 founders
    • CEO Info & Email: Available in our premium reports 🔐
    • Likely to outsource: Available in our premium reports 🔐

    Visit Website →


  103. people having meeting on rectangular brown table


  104. Carmot Therapeutics (Less than $1M)

    Carmot Therapeutics, Inc. provides drugs to treat inflammatory, metabolic, and neurological diseases. The company was founded in 2008 and is based in San Francisco, California.

    • Less than $1M annual revenues
    • 1-10 employees
    • $47M raised in September, 2020
    • 2 founders
    • CEO Info & Email: Available in our premium reports 🔐
    • Likely to outsource: Available in our premium reports 🔐

    Visit Website →


  105. people sitting beside rectangular brown table with laptops


  106. Correlia Biosystems ($1M to $10M)

    Correlia Biosystems, Inc. is a spinout from UC Berkeley developing protein measurement tools that are cost-efficient, rapid, and customizable. Their versatile SimpleScan technology has applications ranging from point-of-care diagnostics to rapid and multiplexed proteomics research.

    • $1M to $10M annual revenues
    • 1-10 employees
    • $9.6M raised in October, 2020
    • 3 founders
    • CEO Info & Email: Available in our premium reports 🔐
    • Likely to outsource: Available in our premium reports 🔐

    Visit Website →


  107. photo of industrial machines near table


  108. Cleave Therapeutics ($1M to $10M)

    Cleave Therapeutics develops oncology pharmaceuticals designed to target neurodengeneration and pathways used by cancer cells to grow. The company is engaged in the discovery of novel, small-molecule drugs that affect protein-degradation pathways, upon which cancer cells depend for survival, enabling patients to get cured from cancer.

    • $1M to $10M annual revenues
    • 1-10 employees
    • $12M raised in August, 2019
    • 2 founders
    • CEO Info & Email: Available in our premium reports 🔐
    • Likely to outsource: Available in our premium reports 🔐

    Visit Website →


  109. people sitting on black chairs


  110. Rio Grande Neurosciences ($10M to $50M)

    Rio Grande Neurosciences manufactures pulsed electromagnetic field therapy devices for the treatment of neuroinflammation. The company develops traumatic brain injury therapeutics current disposable clinical treatment units, and devices for concussion clinical trials. Rio Grande Neurosciences was founded in 2011 and is based in San Francisco, California.

    • $10M to $50M annual revenues
    • 1-10 employees
    • $0.8M raised in February, 2016
    • 2 founders
    • CEO Info & Email: Available in our premium reports 🔐
    • Likely to outsource: Available in our premium reports 🔐

    Visit Website →


  111. man in gray sweatshirt sitting on chair in front of iMac


  112. Vineti ($1M to $10M)

    Vineti is a commercial cloud-based platform that expands patient access to life-saving cells and gene therapies. The software solution offers an independent, purpose-built enterprise solution that is essential for enabling the growth and wide distribution of transformative personalized therapeutics, such as CAR-T cell therapies, for the treatment of late-stage cancer. The Vineti Personalized Therapy Management (PTM) ® platform automates patient-centric supply chains for a wide range of advanced therapies, in all phases of clinical development and commercial operations. Veneti aims to solve the key challenges patients, medical providers, pharmaceutical companies, and regulators face in the delivery and commercialization of personalized medicine. Amy DuRoss, Heidi M. Hagen, Malek Faham, Razmik Abnous, and Stephen Ting co-founded Vineti in San Francisco, California in 2016.

    • $1M to $10M annual revenues
    • 101-250 employees
    • $33M raised in October, 2020
    • 5 founders
    • CEO Info & Email: Available in our premium reports 🔐
    • Likely to outsource: Available in our premium reports 🔐

    Visit Website →


  113. men using computers




  114. Women's Health Initiative (Less than $1M)

    Women's Health Initiative (WHI) is a long-term national health study that focuses on strategies for preventing heart disease, breast and colorectal cancer, and osteoporotic fractures in postmenopausal women. These chronic diseases are the major causes of death, disability, and frailty in older women of all races and socioeconomic backgrounds. While WHI continues to focus on strategies to prevent the major causes of death, disability, and frailty in older women, the breadth and richness of the WHI data allow for the exploration and investigation of more research questions on women’s health and aging.

    • Less than $1M annual revenues
    • 11-50 employees
    • $0.4M raised in April, 2016
    • 1 founder
    • CEO Info & Email: Available in our premium reports 🔐
    • Likely to outsource: Available in our premium reports 🔐

    Visit Website →


  115. people sitting and using laptops


  116. Pheronym (Less than $1M)

    Pheronym is creating an all-natural highly effective insect control for agriculture. By leveraging pheromone spray they double nematode’s effectiveness as an organic insecticide to rival chemicals, without any of the negative health or environmental impact.

    • Less than $1M annual revenues
    • 1-10 employees
    • $0.2M raised in June, 2020
    • 2 founders
    • CEO Info & Email: Available in our premium reports 🔐
    • Likely to outsource: Available in our premium reports 🔐

    Visit Website →


  117. rolling armchair beside table


  118. System1 Biosciences ($10M to $50M)

    System1 Biosciences, Inc., is a San Francisco-based neurotherapeutics company that employs phenotypic screening to discover novel drugs for complex neurological and psychiatric diseases such as epilepsy, autism, and schizophrenia, disorders for which current discovery techniques have proved least successful. System1 combines cerebral organoid science, systems neuroscience, robotic automation, and advanced data analytics to discover characterizations of disease never before achievable. These “deep phenotypes” are exploited to identify novel therapeutic targets and drug treatments.

    • $10M to $50M annual revenues
    • 11-50 employees
    • $25M raised in September, 2018
    • 1 founder
    • CEO Info & Email: Available in our premium reports 🔐
    • Likely to outsource: Available in our premium reports 🔐

    Visit Website →


  119. rectangular brown wooden table with chair lot inside building


  120. Spruce Biosciences ($1M to $10M)

    Spruce Biosciences is a clinical-stage biopharmaceutical focused on developing new treatments for rare endocrine disorders. The company is driven by its mission is to develop meaningful therapies for patients with rare diseases affecting the hypothalamic-pituitary-adrenal. They are committed to transforming the quality of life for patients who have been underserved by scientific innovation.

    • $1M to $10M annual revenues
    • 1-10 employees
    • $88M raised in February, 2020
    • 1 founder
    • CEO Info & Email: Available in our premium reports 🔐
    • Likely to outsource: Available in our premium reports 🔐

    Visit Website →


  121. three women sitting around table using laptops


  122. MicroByre (Less than $1M)

    MicroByre is a biotechnology company that specializes in microbiology, synthetic biology, molecular biology, and computational biology. It domesticates and then genetically engineers otherwise reluctant, recalcitrant, and rebellious bacteria. It was founded in 2017 and headquartered in California, United States.

    • Less than $1M annual revenues
    • 1-10 employees
    • $2.2M raised in September, 2020
    • 3 founders
    • CEO Info & Email: Available in our premium reports 🔐
    • Likely to outsource: Available in our premium reports 🔐

    Visit Website →


  123. brown and white table and chairs


  124. Delpor (Less than $1M)

    Delpor, Inc. engages in developing and acquiring drug delivery technologies that enable the sustained or pattern specific release of proteins, peptides, and small molecules through a small non-mechanical subcutaneous implant. Its technologies include Prozor, which is used for the delivery of antipsychotics and other small molecule drugs from a non-mechanical implantable drug delivery device; NANOPOR, a non-mechanical implantable drug delivery device in which sustained release is provided by membrane architecture; and Delos PUMP, a self-contained and electro-osmotically driven implantable drug delivery device to deliver drugs in predetermined patterns. The company was incorporated in 2009 and is based in San Francisco, California.

    • Less than $1M annual revenues
    • 1-10 employees
    • $1M raised in March, 2016
    • 2 founders
    • CEO Info & Email: Available in our premium reports 🔐
    • Likely to outsource: Available in our premium reports 🔐

    Visit Website →


  125. grey wooden table and black leather rolling chairs


  126. rBIO (Less than $1M)

    Pharmaceutical Manufacturing Using Synthetic Biology

    • Less than $1M annual revenues
    • 1-10 employees
    • $0.1M raised in February, 2020
    • 2 founders
    • CEO Info & Email: Available in our premium reports 🔐
    • Likely to outsource: Available in our premium reports 🔐

    Visit Website →


  127. tennis table in room


  128. Audentes Therapeutics ($10M to $50M)

    Audentes Therapeutics is a biotechnology company committed to the development and commercialization of innovative new gene therapy treatments for people with serious rare diseases. We are a focused, experienced and passionate team driven by the goal of improving the lives of patients.

    • $10M to $50M annual revenues
    • 251-500 employees
    • $65M raised in October, 2015
    • 2 founders
    • CEO Info & Email: Available in our premium reports 🔐
    • Likely to outsource: Available in our premium reports 🔐

    Visit Website →


  129. rectangular brown wooden table


  130. Nurix Therapeutics ($10M to $50M)

    Nurix develops small molecule inhibitors for the treatment of proliferative and degenerative diseases. The company’s product engine leverages a deep mechanistic understanding of the UPS to deliver effective small molecule drug candidates with the potential to make a dramatic difference for patients. Nurix drugs control ubiquitin E3 ligases, the key enzymes responsible for protein breakdown in human cells, as a unique therapeutic approach to treat a broad range of diseases. The company discovers drugs that harness the body's natural process to control protein levels. Their focus is on developing drugs to treat cancer including the novel, small molecule immuno-oncology agents. Nurix was founded in 2009 by internationally recognized experts in the ubiquitin-proteasome field and is funded by leading life science investors, Third Rock Ventures, and The Column Group. The company is headquartered in San Francisco, California.

    • $10M to $50M annual revenues
    • 51-100 employees
    • $120M raised in March, 2020
    • 3 founders
    • CEO Info & Email: Available in our premium reports 🔐
    • Likely to outsource: Available in our premium reports 🔐

    Visit Website →


  131. grayscale photo of people in room


  132. LevitasBio ($1M to $10M)

    Levitas, Inc. is redefining cellular analytics with its novel platform magnetic levitation technology. Their disruptive technology overcomes the current technological limitation of cellular analysis by providing label-free, simple, and universal methods of analysis. The company's platform, the LeviCell enables studies and beneficial uses of previously inaccessible, high-value primary samples, and sensitive cell types regardless of the starting cell number, viability, or sensitivity to processing.

    • $1M to $10M annual revenues
    • 11-50 employees
    • $18M raised in January, 2021
    • 3 founders
    • CEO Info & Email: Available in our premium reports 🔐
    • Likely to outsource: Available in our premium reports 🔐

    Visit Website →


  133. two men using computers


  134. Equator Therapeutics ($1M to $10M)

    Equator Therapeutics develops a drug that burns calories and improves metabolism. It offers a drug that can solve obesity and type 2 diabetes problem because it addresses the root cause of metabolic disorders. Its drug will target mitochondria, the powerhouse of the cell. It will activate the protein that mitochondria naturally use to produce heat. The company's approach has been proven to reverse obesity and type 2 diabetes in animals. It has developed a high-throughput drug discovery platform to identify compounds that selectively activate its target protein, without side effects.

    • $1M to $10M annual revenues
    • 1-10 employees
    • $0.2M raised in March, 2020
    • 2 founders
    • CEO Info & Email: Available in our premium reports 🔐
    • Likely to outsource: Available in our premium reports 🔐

    Visit Website →


  135. group of people sitting beside rectangular wooden table with laptops


  136. TRELYS (Less than $1M)

    Trelys, Inc. operates in the biotechnology sector. The company was incorporated in 2012 and is based in San Francisco, California.

    • Less than $1M annual revenues
    • 11-50 employees
    • $0.1M raised in April, 2017
    • 1 founder
    • CEO Info & Email: Available in our premium reports 🔐
    • Likely to outsource: Available in our premium reports 🔐

    Visit Website →




  137. Tenaya Therapeutics ($1M to $10M)

    Tenaya Therapeutics is a developer of novel therapies designed to offer treatment for heart disease. The company's therapies address heart failure through multipronged efforts that target the fundamental cellular pathologies present in diseased cardiac muscle and that leverage cutting-edge research in cardiac development and regeneration, enabling physicians to regenerate heart tissue, and additional programs focused on cardiomyopathies.

    • $1M to $10M annual revenues
    • 11-50 employees
    • $92M raised in October, 2019
    • 6 founders
    • CEO Info & Email: Available in our premium reports 🔐
    • Likely to outsource: Available in our premium reports 🔐

    Visit Website →


  138. man in black jacket sitting on chair


  139. Global Blood Therapeutics ($1M to $10M)

    GBT is a clinical-stage biopharmaceutical company that focuses on discovering, developing, and delivering innovative treatments that provide hope to underserved patient communities. GBT is developing its product candidate, voxelotor, as an oral, once-daily therapy for sickle cell disease. It was founded in 2012 and headquartered in San Francisco, California.

    • $1M to $10M annual revenues
    • 51-100 employees
    • $48M raised in January, 2015
    • 6 founders
    • CEO Info & Email: Available in our premium reports 🔐
    • Likely to outsource: Available in our premium reports 🔐

    Visit Website →


  140. selective focus photography of desk lamp on table


  141. Alector ($10M to $50M)

    Alector is combining state-of-the-art antibody technology and recent discoveries in neuroimmunology and human genetics to develop novel therapeutics for Alzheimer’s disease, other forms of dementia, and mechanistically related neurodegenerative disorders. Alector’s strategy is to efficiently generate and validate antibody drugs with unique functional properties that engage key disease-altering targets. This approach is enabled by a strategic alliance with Adimab, the industry leader in discovery and optimization of antibody therapeutics. Alector is currently developing leads for 4 major targets and anticipates taking 2 of these through pre-clinical development and IND enabling studies within 24 months. Alector has incorporated a highly integrated and lean biotechnology structure with extensive outsourcing that supports core scientific and management teams.

    • $10M to $50M annual revenues
    • 101-250 employees
    • $133M raised in July, 2018
    • 3 founders
    • CEO Info & Email: Available in our premium reports 🔐
    • Likely to outsource: Available in our premium reports 🔐

    Visit Website →


  142. people using desktop computer inside office


  143. Singular Bio (Less than $1M)

    Singular Bio's technology provides single molecule analysis of a patient's DNA, giving exquisite sensitivity for detecting many common conditions. The company's mission is to expand access to fundamental healthcare information by making advanced genetic tests available to everyone.

    • Less than $1M annual revenues
    • 1-10 employees
    • $6.6M raised in January, 2019
    • 1 founder
    • CEO Info & Email: Available in our premium reports 🔐
    • Likely to outsource: Available in our premium reports 🔐

    Visit Website →


  144. architectural photo of buildings during daytime


  145. Holy Grail (Less than $1M)

    Holy Grail is an artificial intelligence company based in San Francisco, California.

    • Less than $1M annual revenues
    • 1-10 employees
    • $0.2M raised in August, 2019
    • 2 founders
    • CEO Info & Email: Available in our premium reports 🔐
    • Likely to outsource: Available in our premium reports 🔐

    Visit Website →


  146. people sitting in front of computer monitors


  147. Benchling ($1M to $10M)

    Benchling is the modern software platform purpose-built for life science R&D. Hundreds of thousands of scientists using cutting-edge techniques like CRISPR, CAR-T immunotherapy, and genetic engineering depend on our suite of cloud applications to design DNA, collaborate on experiments, manage research workflows, and make critical R&D decisions. Benchling is powering breakthrough research on biotherapeutics, biofuels, and biomaterials at leading life science companies and the world's most renowned academic labs. The company is focusing on life science collaboration, both private and public, through creating cloud-based software tools for digital DNA sequence editing, designing and running experiments, analyzing data, and sharing research. Benchling software includes an electronic lab notebook that allows researchers to document their experiments. It was founded in 2012 and is headquartered in San Francisco, California, United States.

    • $1M to $10M annual revenues
    • 101-250 employees
    • $50M raised in May, 2020
    • 3 founders
    • CEO Info & Email: Available in our premium reports 🔐
    • Likely to outsource: Available in our premium reports 🔐

    Visit Website →


  148. people standiunmg


  149. CytoVale (Less than $1M)

    Categorized is a medical technology company that revolutionizes diagnostics using cell mechanics and machine learning. The company was founded in 2013 by Ajay Shah and Dino Di Carlo and is based in San Francisco, California, United States.

    • Less than $1M annual revenues
    • 11-50 employees
    • $8M raised in January, 2021
    • 2 founders
    • CEO Info & Email: Available in our premium reports 🔐
    • Likely to outsource: Available in our premium reports 🔐

    Visit Website →


  150. people sitting on chairs near tables during daytime


  151. Tunitas Therapeutics (Less than $1M)

    Tunitas Therapeutics is a privately held biopharmaceutical company that is poised to develop unique and precisely targeted protein therapeutics that will dramatically change the lives of allergy sufferers. With Tunitas’ proteins, patients receive a treatment regimen in their allergist’s office that will alter the natural course of their disease, providing a therapeutic option with long-lasting benefit.

    • Less than $1M annual revenues
    • 1-10 employees
    • $10M raised in September, 2015
    • 2 founders
    • CEO Info & Email: Available in our premium reports 🔐
    • Likely to outsource: Available in our premium reports 🔐

    Visit Website →


  152. two women sitting beside table using MacBooks


  153. Cofactor Genomics ($1M to $10M)

    Cofactor Genomics is a Predictive Immune Modeling company driven to remove the barriers that have prohibited the advancement of true precision medicine. Cofactor is enabling the industry to move beyond isolated, single-analyte biomarkers to powerful multidimensional biomarkers using Health Expression Models. Through their molecular, informatic, and database tools, and one of the first CAP-certified, clinical RNA sequencing laboratories, Cofactor enables their partners to deliver more expedient, cost effective, and successful clinical trials.

    • $1M to $10M annual revenues
    • 11-50 employees
    • $18M raised in September, 2017
    • 1 founder
    • CEO Info & Email: Available in our premium reports 🔐
    • Likely to outsource: Available in our premium reports 🔐

    Visit Website →


  154. man and woman sitting at table


  155. Siolta Therapeutics (Less than $1M)

    Siolta Therapeutics is a developer of human microbiome therapeutics intended to prevent and treat inflammatory diseases. The company leverages its deep knowledge of the developing gut microbiome and its role in promoting immune tolerance to develop targeted microbial therapeutics and companion diagnostics for the prevention and treatment of inflammatory diseases, enabling medical researchers to harness information from human microbiome studies to design next-generation microbial therapeutics to prevent inflammatory processes.

    • Less than $1M annual revenues
    • 1-10 employees
    • $30M raised in September, 2020
    • 2 founders
    • CEO Info & Email: Available in our premium reports 🔐
    • Likely to outsource: Available in our premium reports 🔐

    Visit Website →


  156. men sitting of chair inside room


  157. Syapse ($1M to $10M)

    Syapse works with leading health systems, life sciences companies, and regulators to accelerate real-world evidence to improve the outcomes of cancer patients. By bringing these organizations together into the Syapse Learning Health Network, Syapse has built one of the world’s largest networks dedicated to improving outcomes in cancer care through improved precision medicine. Syapse and its partners are working towards a future in which all cancer patients have access to the quality of care they need. The company was founded in 2008 and is headquartered in San Francisco, California.

    • $1M to $10M annual revenues
    • 101-250 employees
    • $30M raised in May, 2020
    • 2 founders
    • CEO Info & Email: Available in our premium reports 🔐
    • Likely to outsource: Available in our premium reports 🔐

    Visit Website →


  158. brown wooden table and chairs


  159. Olema Oncology ($1M to $10M)

    Olema is a preclinical biotechnology company developing new drugs for the treatment and prevention of estrogen receptor (ER) positive breast cancer. The company focuses on the discovery, development, and commercialization of targeted therapies for women's cancers. It leverages the knowledge of the molecular action of the ER to design compounds that are superior to both the current drugs and those in development. Olema leverages their deep understanding of endocrine-driven cancers, nuclear receptors, and mechanisms of acquired resistance with the goal of transforming the standard of care for pre- and post-menopausal women living with cancer by developing more convenient and effective therapies.

    • $1M to $10M annual revenues
    • 11-50 employees
    • $85M raised in October, 2020
    • 2 founders
    • CEO Info & Email: Available in our premium reports 🔐
    • Likely to outsource: Available in our premium reports 🔐

    Visit Website →


  160. people having meeting on rectangular brown table


  161. Perfuse Therapeutics ($10M to $50M)

    Perfuse Therapeutics specializes in developing therapies for the treatment of eye disease. The company is pursuing a novel mechanism to treat various eye diseases, starting with glaucoma, by improving retinal perfusion.

    • $10M to $50M annual revenues
    • 1-10 employees
    • $9M raised in July, 2020
    • 1 founder
    • CEO Info & Email: Available in our premium reports 🔐
    • Likely to outsource: Available in our premium reports 🔐

    Visit Website →


  162. people sitting beside rectangular brown table with laptops


  163. Wild Type ($1M to $10M)

    Wild Type is an agtech platform based in San Francisco, California. Wild Type aims to create clean and sustainable fish and meat. They use cellular agriculture technologies to address the most pressing challenges of the generation: climate change, food security, and health. They are looking for committed scientists to fundamentally redefine how the world sources healthy and delicious meat.

    • $1M to $10M annual revenues
    • 11-50 employees
    • $12.5M raised in October, 2019
    • 2 founders
    • CEO Info & Email: Available in our premium reports 🔐
    • Likely to outsource: Available in our premium reports 🔐

    Visit Website →


  164. photo of industrial machines near table


  165. Denali Therapeutics ($10M to $50M)

    Denali Therapeutics is a biotechnology company focused on the discovery and development of therapies for patients with neurodegenerative diseases, including Alzheimer's disease, Parkinson's disease, ALS and others. Denali was founded by scientists, industry experts and investors who share the vision that recent scientific insights into the genetic causes and biological processes underlying neurodegenerative disease, together with new translational medicine tools, offer an unprecedented opportunity to discover and develop effective medicines. Denali is rigorously pursuing a science-driven approach to translational medicine and clinical development.

    • $10M to $50M annual revenues
    • 251-500 employees
    • $130M raised in August, 2016
    • 3 founders
    • CEO Info & Email: Available in our premium reports 🔐
    • Likely to outsource: Available in our premium reports 🔐

    Visit Website →


  166. people sitting on black chairs


  167. Darmiyan ($10M to $50M)

    Darmiyan has developed a novel, proprietary, patent-protected technology called The Virtual Microscope (Software Algorithm). Using a non-invasive routine clinical brain MRI scan, The Virtual Microscope technology looks into the human brain and localizes and quantifies cell distortion (neurodegeneration) in every voxel of brain MRI generating new brain maps. The first clinical product of this technology is BrainSee, an AI-powered algorithm that has completed a successful third-party validation in the US and Canada establishing a remarkable accuracy and consistency for prognosis of mild cognitive impairment. It is built on over 40 years of cutting-edge neuroscience research combined with advanced medical image analysis and AI, and has received official approval from the late Prof. Paul Greengard, Nobel Laureate in Physiology/ Medicine 2000.

    • $10M to $50M annual revenues
    • 11-50 employees
    • $6.4M raised in April, 2020
    • 3 founders
    • CEO Info & Email: Available in our premium reports 🔐
    • Likely to outsource: Available in our premium reports 🔐

    Visit Website →


  168. man in gray sweatshirt sitting on chair in front of iMac


  169. BehavioSec (Less than $1M)

    BehavioSec is the industry’s pioneer and technology leader for behavioral biometrics and continuous authentication, safeguarding millions of users and billions of transactions today. Deployed across Global 2000 companies to dramatically reduce fraud, friction, threat and theft, BehavioSec verifies and protects human digital identities by understanding how we uniquely type and swipe across our ever-changing devices. Whether used in the Cloud or on-premises, BehavioSec delivers the superior user experience, precision and scale needed by organizations to keep customers engaged while catching evasive, real-time attacks other solutions miss. Founded in the Nordics in 2008 out of groundbreaking research, BehavioSec works with organizations like DARPA, is recognized as a Gartner Cool Vendor and RSA Innovation Sandbox Finalist, and has earned investment from leading firms like Forgepoint Capital, Cisco, ABN AMRO, Conor Ventures, and Octopus Ventures. Headquartered in San Francisco, CA with offices worldwide, BehavioSec is ready to help you reduce risk, improve compliance and digitally transform your distributed workforce and customer experience.

    • Less than $1M annual revenues
    • 11-50 employees
    • $17.5M raised in January, 2018
    • 2 founders
    • CEO Info & Email: Available in our premium reports 🔐
    • Likely to outsource: Available in our premium reports 🔐

    Visit Website →


  170. men using computers


  171. CH4 Global (Less than $1M)

    CH4 Global is an aquaculture solutions provider dedicated to urgently impacting climate change. Lead by a world-class team of senior business builders, scientists and entrepreneurs, the company is initially leveraging proven science and technology for growing seaweed into innovative new livestock supplement that reduces methane produced by cows by up to 90%. Among early investors are a select group of prominent family offices and private investors. CH4 Global have also received non-dilutive capital support from government organizations from around the world. CH4 Global is a Delaware corporation based in San Francisco, CA.

    • Less than $1M annual revenues
    • 1-10 employees
    • $3M raised in September, 2020
    • 2 founders
    • CEO Info & Email: Available in our premium reports 🔐
    • Likely to outsource: Available in our premium reports 🔐

    Visit Website →




  172. Siluria Technologies ($10M to $50M)

    Siluria Technologies is a materials innovation company solving global challenges for partners in the natural gas, chemicals and fuel industries. Integrating nanotechnology, biotechnology and chemical engineering, Siluria has developed a solution to the grand challenge of efficient manufacturing: the ability to produce chemicals and fuels from a cheaper, more abundant resource than oil. The company's economically superior, energy-efficient platform converts natural gas into the same materials manufactured today using current industry infrastructure. Siluria's world-class R&D and engineering teams are rapidly commercializing the company's technology to pilot-scale production in close dialogue with the world's largest chemical and fuel companies.Siluria's backers include Alloy Ventures, ARCH Venture Partners, Kleiner Perkins Caufield & Byers, Altitude Life Science Ventures, Lux Capital, and Presidio Ventures.

    • $10M to $50M annual revenues
    • 51-100 employees
    • $45M raised in July, 2016
    • 2 founders
    • CEO Info & Email: Available in our premium reports 🔐
    • Likely to outsource: Available in our premium reports 🔐

    Visit Website →


  173. people sitting and using laptops


  174. ViewPoint Therapeutics ($1M to $10M)

    ViewPoint Therapeutics is a biotechnology company dedicated to the development of treatments for diseases of protein misfolding, including cataracts. The company's crystallin stabilizers include a small molecule that is active in preclinical models of age-related cataracts via a target-based screening and optimization effort, providing physicians with drugs to prevent or reverse protein misfolding, which is implicated in numerous common disorders of aging including cataracts, presbyopia, and neurodegenerative diseases.

    • $1M to $10M annual revenues
    • 11-50 employees
    • $35M raised in March, 2018
    • 2 founders
    • CEO Info & Email: Available in our premium reports 🔐
    • Likely to outsource: Available in our premium reports 🔐

    Visit Website →


  175. rolling armchair beside table


  176. Neurona Therapeutics ($1M to $10M)

    Neurona Therapeutics is a pre-clinical stage biotechnology company that was founded by four neuroscientists and stem cell pioneers at The University of California, San Francisco. They are focused on the discovery and development of cell-based therapies to treat intractable neurological disease. Its initial aim is to generate therapeutic compositions of a specific type of nerve cell (or neuron) for targeted delivery into the injured nervous system. Based on nearly two decades of research, they believe that particular subpopulations of neurons have the unique ability to integrate and repair dysregulated neural circuits. Its talented team of scientists, scientific advisors, and board directors is working to accelerate breakthrough treatments for patients with significant unmet medical needs.

    • $1M to $10M annual revenues
    • 11-50 employees
    • $15M raised in November, 2019
    • 1 founder
    • CEO Info & Email: Available in our premium reports 🔐
    • Likely to outsource: Available in our premium reports 🔐

    Visit Website →


  177. rectangular brown wooden table with chair lot inside building


  178. BioQ Pharma ($10M to $50M)

    BioQ Pharma is a late stage specialty pharmaceutical company focused on developing and commercializing a portfolio of large volume ready-to-use infusible pharmaceuticals. Our vision is to set a new standard of care in the presentation and administration of infusible pharmaceuticals via our proprietary unit-dose infusion systems that can be deployed quickly and conveniently at the point of care with one touch. Our infusion platform is intended to address some of the most pressing unmet needs in infusion today: cost, medication error, sterility, efficiency, and patient quality of life.

    • $10M to $50M annual revenues
    • 11-50 employees
    • $55M raised in August, 2017
    • 1 founder
    • CEO Info & Email: Available in our premium reports 🔐
    • Likely to outsource: Available in our premium reports 🔐

    Visit Website →


  179. three women sitting around table using laptops


  180. Mekonos Inc. ($1M to $10M)

    Mekonos is a Silicon Valley Venture-backed technology company — creating a proprietary cell-engineering platform based on scalable silicon technology for our partners engaged in drug discovery and development.

    • $1M to $10M annual revenues
    • 1-10 employees
    • $4.6M raised in November, 2020
    • 3 founders
    • CEO Info & Email: Available in our premium reports 🔐
    • Likely to outsource: Available in our premium reports 🔐

    Visit Website →


  181. brown and white table and chairs


  182. SillaJen (Less than $1M)

    SillaJen, Inc. is a South Korean based biotechnology company headquartered in Busan South Korea, with satellite offices in Seoul South Korea and Financial District, San Francisco. The company is focused on the development and commercialization of oncolytic immunotherapy products using the SOLVE™ platform, including its lead product Pexa-Vec, which is currently in Phase 3 trials for the treatment of advanced primary liver cancer. 2003. Jennerex, Inc. (San Francisco, USA) was established. 2014. SillaJen acquires Jennerex, Inc. 2015. In April 2015. SillaJen reached agreement with the US FDA on a Special Protocol Assessment (SPA) for multinational Phase 3 clinical trial of Pexa-Vec in Advanced Liver Cancer. 2015. In October 2015, SillaJen is selected as the major developer for the Government project of “Global State-of-the-art technology development for biomedical products." 2016. In January 2016, SillaJen announces first patient randomized in multinational Phase 3 trial for Pexa-Vec in Advanced Liver Cancer. In December 2016. SillaJen is listed on KOSDAQ market in South Korea. 2017. In may 2017, Sillajen signs collaborative agreement with Regeneron Pharmaceuticals for development of combination therapy with Pexa-Vec and immune checkpoint inhibitors. In July 2017, SillaJen received approval from the China CFDA to commence phase 3 clinical trial for Pexa-Vec in liver cancer. In Aug 2017, Sillajen signs collaborative agreement with the National Cancer Institute for development of combination therapy with Pexa-Vec and immune checkpoint inhibitors.

    • Less than $1M annual revenues
    • 101-250 employees
    • $12M raised in March, 2016
    • 1 founder
    • CEO Info & Email: Available in our premium reports 🔐
    • Likely to outsource: Available in our premium reports 🔐

    Visit Website →


  183. grey wooden table and black leather rolling chairs


  184. Ovipost (Less than $1M)

    Ovipost, a new startup looking to optimize the right conditions for a cricket grower to get the most yield from a generation of eggs without having to lose a bunch of crickets in the process. At its heart, Ovipost is aimed at being a set of tools that will help farmers figure out the best way to optimize their cricket yield by managing initial problems like the proper volume of cricket eggs as well as traditional problems cricket farmers face. The end goal is to reduce the overall labor cost, taking the process from less of an art — and listening for the right song — to more one that farmers can augment with technology. Ovipost is launching out of Y Combinator’s winter class this year.

    • Less than $1M annual revenues
    • 1-10 employees
    • $0.1M raised in January, 2018
    • 1 founder
    • CEO Info & Email: Available in our premium reports 🔐
    • Likely to outsource: Available in our premium reports 🔐

    Visit Website →


  185. tennis table in room


  186. Aizon ($1M to $10M)

    Aizon is an AI software provider that transforms manufacturing operations with the use of advanced analytics, artificial intelligence, and other smart factory technologies focused on optimizing production within highly regulated industries. The Aizon AI platform seamlessly integrates unlimited sources of structured and unstructured data to deliver actionable insights across all manufacturing sites. Aizon offers an intuitive way to gain meaningful operational intelligence by enabling real-time visibility and predictive insights in a GxP compliant manner with end-to-end data integrity.

    • $1M to $10M annual revenues
    • 51-100 employees
    • $15M raised in November, 2019
    • 3 founders
    • CEO Info & Email: Available in our premium reports 🔐
    • Likely to outsource: Available in our premium reports 🔐

    Visit Website →


  187. rectangular brown wooden table


  188. Fountain Therapeutics ($1M to $10M)

    Fountain Therapeutics is discovering and developing treatments for aging-associated diseases. Fountain Therapeutics was founded with the belief that a future in which we live healthier lives longer is more desirable than one in which the company continues to be afflicted by the disease of aging. The company builds a transformative model of aging that re-creates many of the complex hallmark features of aging but in a laboratory dish. We are combining this powerful cellular model with the latest in artificial intelligence and computer vision to develop a disruptive unbiased platform for the identification of novel targets and potential therapeutics.

    • $1M to $10M annual revenues
    • 1-10 employees
    • $6M raised in February, 2020
    • 3 founders
    • CEO Info & Email: Available in our premium reports 🔐
    • Likely to outsource: Available in our premium reports 🔐

    Visit Website →


  189. grayscale photo of people in room


  190. Aeovian Pharmaceuticals ($1M to $10M)

    Aeovian Pharmaceuticals is a San Francisco Bay Area-based biopharmaceutical company aiming to discover, develop, and commercialize innovative therapeutics for the treatment of rare and age-related diseases. The company is developing compounds to modulate molecular pathways that address the underlying causes of disease initiation and progression, such as oxidative, cellular and environmental stress. Aeovian Pharmaceuticals was founded in 2012.

    • $1M to $10M annual revenues
    • 1-10 employees
    • $37M raised in October, 2019
    • 1 founder
    • CEO Info & Email: Available in our premium reports 🔐
    • Likely to outsource: Available in our premium reports 🔐

    Visit Website →


  191. two men using computers


  192. Naked Biome ($1M to $10M)

    Naked Biome is a microbiome-based therapeutics company, launching advanced therapy to treat and prevent skin disease. They build an advanced drug discovery genomics platform for the treatment and continual improvement of skin diseases and health. Our proprietary microbiome-based approach to skin therapy leverages the power of beneficial bacteria on the skin to eliminate harmful bacteria and restore skin to a healthy state. We have successfully completed a phase IB in acne demonstrating both safety and early trends in efficacy.

    • $1M to $10M annual revenues
    • 1-10 employees
    • $5M raised in April, 2017
    • 1 founder
    • CEO Info & Email: Available in our premium reports 🔐
    • Likely to outsource: Available in our premium reports 🔐

    Visit Website →


  193. group of people sitting beside rectangular wooden table with laptops


  194. Pembient (Less than $1M)

    Pembient is leveraging advances in biotechnology to fabricate wildlife products, such as rhino horn and elephant ivory, at prices below the levels that induce poaching. Their goal is to replace the illegal wildlife trade, a $20B black market, the fourth largest after drug, arms, and human trafficking, with sustainable commerce. Pembient is an IndieBio SF 2015 company.

    • Less than $1M annual revenues
    • 1-10 employees
    • $0.1M raised in January, 2015
    • 2 founders
    • CEO Info & Email: Available in our premium reports 🔐
    • Likely to outsource: Available in our premium reports 🔐

    Visit Website →




  195. Memoir Health (Less than $1M)

    Memoir Health was a healthcare services company that provided comprehensive, evidence-based care for chronic pain patients. This care utilized a multidisciplinary approach to addresses the cognitive, sensory and functional dimensions of chronic pain, rather than focusing on interventional procedures such as injections or surgery. In addition to providing direct care, a dedicated research arm of the company worked to advance techniques in neuromodulation, biomarker identification and VR therapies. Memoir Health was partially acquired by Lumeo Health in August 2020, led by former Chief Strategy Officer Dr. Richard Goldberg.

    • Less than $1M annual revenues
    • 1-10 employees
    • $7.5M raised in March, 2019
    • 2 founders
    • CEO Info & Email: Available in our premium reports 🔐
    • Likely to outsource: Available in our premium reports 🔐

    Visit Website →


  196. man in black jacket sitting on chair


  197. Unlearn.AI ($1M to $10M)

    Unlearn is the only company using AI to create Digital Twins to populate Intelligent Control Arms in clinical studies. By leveraging historical datasets and disease-specific machine-learning models, Unlearn generates virtual placebo patients, created from actual patient baseline data in clinical studies. This novel approach increases trial power and confidence, accelerates trial timelines, and enables patient level insights. Unlearn was founded in 2017 by a team of world-class machine learning scientists who shared a vision of using machine learning to streamline clinical trials. Unlearn has received a total of $20M in funding, most recently in a Series A extension lead by Eisai, Epic Ventures, and Alumni Ventures. Unlearn has authored a peer-reviewed publication in Nature, and is partnering with one of the world’s leading pharma companies. Digital Twins are currently part of an ongoing pivotal Alzheimer’s Disease trial. In 2020, Unlearn was named a CB Insights Digital Health 150 Company, and the winner of the Innovation Showcase at CNS Summit. Unlearn continues to have discussions with regulators, industry leaders, and other key stakeholders, and is seeking partners to help drive innovation in clinical research using AI.

    • $1M to $10M annual revenues
    • 11-50 employees
    • $3M raised in November, 2020
    • 1 founder
    • CEO Info & Email: Available in our premium reports 🔐
    • Likely to outsource: Available in our premium reports 🔐

    Visit Website →


  198. selective focus photography of desk lamp on table


  199. PostEra ($1M to $10M)

    PostEra uses machine learning to close the design-make-test loop of drug discovery and reduce our clients' cycle times. We are currently leading an international team of scientists to find a COVID antiviral via on open science initative. Consider contributing your expertise to the initiative here: https://postera.ai/covid

    • $1M to $10M annual revenues
    • 1-10 employees
    • $2.3M raised in March, 2020
    • 3 founders
    • CEO Info & Email: Available in our premium reports 🔐
    • Likely to outsource: Available in our premium reports 🔐

    Visit Website →


  200. people using desktop computer inside office


  201. Dreem ($1M to $10M)

    Dreem is a neurotechnology company building consumer technology that stimulates the brain to enhance human potential. The company's product, Dreem is a wearable device that enhances the quality of deep sleep. The device monitors brainwaves, analyzes user's sleep and stimulates the brain with sound in order to extend the amount of deep sleep, improving human performance throughout the day.

    • $1M to $10M annual revenues
    • 51-100 employees
    • $35M raised in June, 2018
    • 2 founders
    • CEO Info & Email: Available in our premium reports 🔐
    • Likely to outsource: Available in our premium reports 🔐

    Visit Website →


  202. architectural photo of buildings during daytime


  203. Twist Bioscience ($10M to $50M)

    Twist Bioscience is a synthetic DNA production for specialty chemical compounds and drug development. At Twist Bioscience Corporation, they work in the service of customers who are changing the world for the better. In fields such as health care, agriculture, industrial chemicals, and data storage, by using our synthetic DNA tools, their customers are developing ways to better lives and improve the sustainability of the planet. They believe that the faster their customers succeed, the better for all of them, and Twist Bioscience is uniquely positioned to help accelerate their efforts. Their innovative silicon-based DNA Synthesis Platform provides precision at a scale that we believe is otherwise unavailable to their customers. their platform technologies overcome inefficiencies and enable cost-effective, rapid, precise, high-throughput synthesis and sequencing, providing both the quality and quantity of the tools they need to rapidly realize the opportunity ahead. Twist Bioscience was founded in 2013 and is headquartered in San Francisco, California.

    • $10M to $50M annual revenues
    • 251-500 employees
    • $50M raised in April, 2018
    • 2 founders
    • CEO Info & Email: Available in our premium reports 🔐
    • Likely to outsource: Available in our premium reports 🔐

    Visit Website →


  204. people sitting in front of computer monitors


  205. Coral Genomics (Less than $1M)

    Coral Genomics generates novel data sets to fill gaps in large-scale biobanks with clinical diagnostics that facilitate medication selection for diverse populations. Integrating molecular, functional, and clinical factors to optimize treatment for chronic disease, Coral works with healthcare systems to provide end-to-end precision medicine support from next-generation sequencing through patient/provider facing healthcare reports that create more personalized and efficient healthcare delivery.

    • Less than $1M annual revenues
    • 1-10 employees
    • $2M raised in October, 2020
    • 1 founder
    • CEO Info & Email: Available in our premium reports 🔐
    • Likely to outsource: Available in our premium reports 🔐

    Visit Website →


  206. people standiunmg


  207. Zephyr Health ($1M to $10M)

    Zephyr Health operates as an insights-as-a-service solution built specifically for life sciences companies addressing critical business and patient needs. Zephyr Illuminate™ helps pharmaceutical, biotechnology, and medical device companies make confident decisions faster across the entire lifecycle with precise and predictive data insights.

    • $1M to $10M annual revenues
    • 51-100 employees
    • $17.5M raised in August, 2015
    • 1 founder
    • CEO Info & Email: Available in our premium reports 🔐
    • Likely to outsource: Available in our premium reports 🔐

    Visit Website →


  208. people sitting on chairs near tables during daytime


  209. 89bio ($1M to $10M)

    89bio is a clinical-stage biopharmaceutical company focused on rapidly advancing our lead product candidate, BIO89-100, through clinical development for the treatment of non-alcoholic steatohepatitis (NASH). BIO89-100 is a specifically engineered glycoPEGylated analog of fibroblast growth factor 21 (FGF21). It may be a differentiated FGF21 therapy, and we believe it has the potential to become a mainstay of therapy for NASH given its ability to address the key liver pathologies (steatosis and fibrosis) and underlying metabolic dysregulation in patients with NASH. We are also expanding the breadth of indications for BIO89-100 with an initial focus on severe hypertriglyceridemia (SHTG).

    • $1M to $10M annual revenues
    • 11-50 employees
    • $83.8M raised in July, 2020
    • 1 founder
    • CEO Info & Email: Available in our premium reports 🔐
    • Likely to outsource: Available in our premium reports 🔐

    Visit Website →


  210. two women sitting beside table using MacBooks


  211. Attralus ($10M to $50M)

    Attralus is a biopharmaceutical company focusing on creating transformative medicines to improve the lives of patients with systemic amyloidosis. Its proprietary peptide-based pan-amyloid targeting agents have the potential to diagnose and treat all forms and stages of systemic amyloidosis. The company is focused on targeting common pathology in all systemic amyloidosis diseases, with the goal of developing treatments for all subtypes of amyloidosis, including the majority in which there are currently no treatment options.

    • $10M to $50M annual revenues
    • 1-10 employees
    • $25M raised in September, 2020
    • 2 founders
    • CEO Info & Email: Available in our premium reports 🔐
    • Likely to outsource: Available in our premium reports 🔐

    Visit Website →


  212. man and woman sitting at table


  213. Enzyme (Less than $1M)

    Enzyme is building software to help life sciences companies with FDA approval and regulatory compliance. Using Enzyme’s software, those companies can avoid spending money on costly consultants which in turn can reduce their compliance costs by up to 50 percent. Since 10 percent of all personnel in biopharma and life sciences companies are related to regulatory issues, it can lower headcount as well. Perhaps most importantly, Enzyme can also make it easier and faster for those companies to bring their products to market.

    • Less than $1M annual revenues
    • 1-10 employees
    • $1.9M raised in October, 2017
    • 2 founders
    • CEO Info & Email: Available in our premium reports 🔐
    • Likely to outsource: Available in our premium reports 🔐

    Visit Website →


  214. men sitting of chair inside room


  215. Perlara (Less than $1M)

    Perlara, PBC is the first Public Benefit Corporation accelerating precision drug discovery for 5,000+ rare genetic diseases. PLab uses a platform of CRISPR-engineered animal models (yeast, nematodes, fruit flies and zebrafish) in whole-organism phenotypic screens to generate disease-reversing orphan drug candidates much faster and cheaper than traditional in vitro and cell-based approaches. Their lead discovery programs are Niemann-Pick Type C, a lysosomal storage disorder first described nearly a century ago, and NGLY1 Deficiency, a congenital disorder of glycosylation first diagnosed last year. Their initial pipeline includes, among others, additional lysosomal storage disorders, e.gs, Batten and Mucolipidosis IV, mitochondrial diseases, e.g., Leigh, and peroxisomal biogenesis disorders, e.g., Zellweger.

    • Less than $1M annual revenues
    • 1-10 employees
    • $4.1M raised in August, 2017
    • 2 founders
    • CEO Info & Email: Available in our premium reports 🔐
    • Likely to outsource: Available in our premium reports 🔐

    Visit Website →


  216. brown wooden table and chairs


  217. Delee ($1M to $10M)

    At Delee, we aim to radically change the way cancer is detected, monitored and treated. Through the development of the CytoCatch™, which is a highly sensitive automated benchtop device, we have made possible to rapidly isolate and efficiently analyze circulating tumor cells from blood samples. This innovative technology enables not only the early detection of cancer, but also the continuous monitoring of the disease’s evolution and the effectiveness of therapies that are being administered; increasing the patient’s chances of defeating cancer.

    • $1M to $10M annual revenues
    • 11-50 employees
    • $1.2M raised in April, 2017
    • 2 founders
    • CEO Info & Email: Available in our premium reports 🔐
    • Likely to outsource: Available in our premium reports 🔐

    Visit Website →


  218. people having meeting on rectangular brown table


  219. OccamzRazor ($1M to $10M)

    OccamzRazor is a San Francisco based AI-neuroscience startup that is focused on finding disease modifying treatments for Parkinson's Disease (PD) and other complex diseases. To cure a complex and multifactorial disease like PD, we need to go beyond targeting just a single gene or a single disease mechanism. OccamzRazor consumes and analyzes unstructured and structured biomedical datasets (e.g., published literature, preclinical and clinical trial results), and constructs an exhaustive knowledge graph representing all known information about PD. This graph is used to drive downstream therapeutic insight, augment decision making in biomedical research, and generate strategic therapeutics development.

    • $1M to $10M annual revenues
    • 11-50 employees
    • $4.5M raised in May, 2019
    • 1 founder
    • CEO Info & Email: Available in our premium reports 🔐
    • Likely to outsource: Available in our premium reports 🔐

    Visit Website →


  220. people sitting beside rectangular brown table with laptops


  221. Gyroscope Innovations (Less than $1M)

    Gyroscope Innovations is a new OS for the human body. It was started by Anand Sharma in 2014 as a personal project called April Zero.

    • Less than $1M annual revenues
    • 1-10 employees
    • $0.6M raised in March, 2017
    • 1 founder
    • CEO Info & Email: Available in our premium reports 🔐
    • Likely to outsource: Available in our premium reports 🔐

    Visit Website →


  222. photo of industrial machines near table


  223. Nebula Genomics ($1M to $10M)

    Nebula Genomics is a human genome sequencing and health big data company on a mission to usher in the era of genomic sequencing by building a large and trusted genomic and health data marketplace for consumers, researchers and the medical community. Using blockchain to ensure that consumers maintain control of their data and are compensated for its use, the Nebula marketplace will aggregate a critical mass of rich genetic information that researchers can analyze in order to accelerate drug development, streamline clinical trials, and usher in the era of truly personalized medicine. The company was founded by Harvard genomics pioneer George Church, along with Harvard researchers Dennis Grishin and Kamal Obbad. Founded in 2017, Nebula Genomics has offices in San Francisco, CA and Boston, MA and is backed by investors including Khosla Ventures, Arch Venture Partners, Fenbushi Capital, Mayfield, F-Prime Capital Partners, GreatPoint Ventures, Hemi Ventures and Mirae Asset.

    • $1M to $10M annual revenues
    • 11-50 employees
    • $4.3M raised in October, 2018
    • 3 founders
    • CEO Info & Email: Available in our premium reports 🔐
    • Likely to outsource: Available in our premium reports 🔐

    Visit Website →


  224. people sitting on black chairs


  225. Dropprint Genomics ($10M to $50M)

    Dropprint Genomics provides cell technology and machine learning models that characterize the immune system. It offers big data to the immune system by generating personalized maps of a patient's immune systems to better understand, control, and improve immune health. Jimmie Ye, Meena Subramaniam, and Rachel Gate co-founded San Francisco, California.

    • $10M to $50M annual revenues
    • 1-10 employees
    • $0.2M raised in March, 2020
    • 3 founders
    • CEO Info & Email: Available in our premium reports 🔐
    • Likely to outsource: Available in our premium reports 🔐

    Visit Website →


  226. man in gray sweatshirt sitting on chair in front of iMac


  227. NATURANSA Biotechnology Inc. ($10M to $50M)

    Naturansa is a biotech company that produces alternative sustainable protein from edible insect grown through pre-consumer food waste decomposition. It has built scalable technology that produces insect year-round which then get converted into a protein powder. Through the nutrient cycle in nature, they are working on modern, sustainable, ecologic product and systems by using science and technology.

    • $10M to $50M annual revenues
    • 1-10 employees
    • $0.3M raised in April, 2019
    • 1 founder
    • CEO Info & Email: Available in our premium reports 🔐
    • Likely to outsource: Available in our premium reports 🔐

    Visit Website →


  228. men using computers


  229. Felix Biotechnology (Less than $1M)

    Felix Biotechnology is working to accelerate the deployment of novel biotherapeutics to manage infectious diseases. Felix Biotechnology's bio-therapeutics targets antibiotic-resistant bacteria to manage infectious diseases precisely and effectively, allowing healthcare professionals to manage urgent microbial challenges in human health.

    • Less than $1M annual revenues
    • 1-10 employees
    • $0.2M raised in March, 2020
    • 2 founders
    • CEO Info & Email: Available in our premium reports 🔐
    • Likely to outsource: Available in our premium reports 🔐

    Visit Website →




  230. Arcturus BioCloud ($1M to $10M)

    Arcturus BioCloud is a virtual bio-foundry for rapid prototyping microorganisms using genetic engineering. They’ve simplified the outsourcing of experiments on and yeast by seamlessly integrating genetic engineering technologies into a user-friendly platform that covers the whole genetic engineering cycle. Users can upload on Arcturus BioCloud their biological design, and they will build and test it for them. This way, helping organisations accelerate their process of developing innovative products. For that, they already have in place partnerships with Synbiota and ZymoResearch that provide us with advance technologies. In the following months, they will be adding new partnerships to extend their service portfolio. Their mission is to make more accessible these technologies so that scientists from all around the world can work with the best tools, regardless of their geographical limitations. They also have a great team; they met at Singularity University, and they cover all the domains required for executing the mission. Biotechnology is one of the fastest-growing markets, mainly because of the exponential price reduction of Synthesizing and Sequencing, which is beating Moore’s Law. As the prices decrease, more people will start to create innovations and companies. They see this future very close, and that is why they’ve started providing these technologies that in the following years will be 100x cheaper.

    • $1M to $10M annual revenues
    • 1-10 employees
    • $0.1M raised in June, 2015
    • 4 founders
    • CEO Info & Email: Available in our premium reports 🔐
    • Likely to outsource: Available in our premium reports 🔐

    Visit Website →


  231. people sitting and using laptops


  232. PipelineRx ($1M to $10M)

    PipelineRx is a multi-state organization with an exclusive focus on developing and delivering world-class telepharmacy, leadership development, and on-line community services for hospital and retail pharmacies. The company was founded in 2009 by Brian Roberts and is based in San Francisco, California, United States.

    • $1M to $10M annual revenues
    • 101-250 employees
    • $15.4M raised in October, 2017
    • 1 founder
    • CEO Info & Email: Available in our premium reports 🔐
    • Likely to outsource: Available in our premium reports 🔐

    Visit Website →


  233. rolling armchair beside table


  234. Tag.bio (Less than $1M)

    Tag.bio is a data analytics startup. It combines sophisticated statistical analysis methods with the organic intelligence of its users to find insights in any dataset. Individuals can use its point and click system to perform analysis and share results from enterprise and public datasets. It allows its users to make their own custom protocols to enterprise and public datasets. The platform is available for operations through iOS and Android applications. Tag.bio is a U.S.-based company that was founded in 2013 by Tom Covington and Jesse Paquette.

    • Less than $1M annual revenues
    • 1-10 employees
    • $0.1M raised in March, 2019
    • 2 founders
    • CEO Info & Email: Available in our premium reports 🔐
    • Likely to outsource: Available in our premium reports 🔐

    Visit Website →


  235. rectangular brown wooden table with chair lot inside building


  236. Nivien Therapeutics (Less than $1M)

    Nivien Therapeutics developed the first small molecule inhibitors of the Hippo signaling pathway. Read the Nivien story in The Washington Post: https://www.washingtonpost.com/national/health-science/heres-what-happened-when-i-tried-to-develop-a-new-drug-for-a-deadly-cancer/2019/01/11/

    • Less than $1M annual revenues
    • 1-10 employees
    • $0.6M raised in December, 2017
    • 4 founders
    • CEO Info & Email: Available in our premium reports 🔐
    • Likely to outsource: Available in our premium reports 🔐

    Visit Website →


  237. three women sitting around table using laptops


  238. ZBiotics (Less than $1M)

    ZBiotics is a synthetic biology company founded in 2016 and headquartered in San Francisco, California. The company bioengineers probiotic bacteria for nutraceutical and other applications. ZBiotics is pioneering the use of genetically engineered probiotics to solve intractable problems.

    • Less than $1M annual revenues
    • 1-10 employees
    • $2.3M raised in March, 2020
    • 2 founders
    • CEO Info & Email: Available in our premium reports 🔐
    • Likely to outsource: Available in our premium reports 🔐

    Visit Website →


  239. brown and white table and chairs


  240. Renewal Mill ($1M to $10M)

    Renewal Mill is a next generation ingredient company that upcycles fiber and protein produced during large-scale food manufacturing into high-quality ingredients and products. In doing so, Renewal Mill, the recent winner of IFT's Food Disruption Challenge, is reducing waste and improving nutrition. Partnering with its first pilot facility in Oakland, CA, Renewal Mill uses its proprietary technology to upcycle the byproduct of soymilk manufacturing, called okara, into a high protein, high fiber, gluten free flour. The company uses that flour to create baked good products that are currently sold at convenience stores in the Bay Area and can be found at tech company offices. Renewal Mill will soon be in nationwide distribution and has already started work on additional byproduct sources from other nuts and legumes.

    • $1M to $10M annual revenues
    • 1-10 employees
    • $2.5M raised in January, 2019
    • 1 founder
    • CEO Info & Email: Available in our premium reports 🔐
    • Likely to outsource: Available in our premium reports 🔐

    Visit Website →


  241. grey wooden table and black leather rolling chairs


  242. Nextbiotics ($10M to $50M)

    Nextbiotics is a biotechnology company based in San Francisco, California.

    • $10M to $50M annual revenues
    • 1-10 employees
    • $0.8M raised in January, 2018
    • 3 founders
    • CEO Info & Email: Available in our premium reports 🔐
    • Likely to outsource: Available in our premium reports 🔐

    Visit Website →


  243. tennis table in room


  244. Oyster Point Pharmaceuticals ($100M to $500M)

    Oyster Point Pharma is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of first-in-class pharmaceutical therapies to treat ocular surface diseases. Oyster Point Pharma’s lead product candidate, OC-01, a highly selective nicotinic acetylcholine receptor (nAChR) agonist, is being developed as a nasal spray to treat the signs and symptoms of dry eye disease. Dry eye disease is a chronic, progressive condition that impacts more than 30 million Americans and is growing in prevalence. OC-01’s novel mechanism of action re-establishes tear film homeostasis by activating the trigeminal parasympathetic pathway to stimulate the glands and cells responsible for natural tear film production, known as the Lacrimal Functional Unit (LFU).

    • $100M to $500M annual revenues
    • 11-50 employees
    • $120.8M raised in May, 2020
    • 2 founders
    • CEO Info & Email: Available in our premium reports 🔐
    • Likely to outsource: Available in our premium reports 🔐

    Visit Website →


  245. rectangular brown wooden table


  246. Tempest Therapeutics ($1M to $10M)

    Tempest Therapeutics is a biotechnology company that focuses on small molecule therapeutics that modulate anti-tumor immunity pathways. The company has a balanced and deep pipeline consisting of first-in-class and best-in-class small molecule therapeutics, which modulate distinct pathways relevant to mounting an effective anti-tumor response. Tempest Therapeutics was established in 2011 and is headquartered in San Francisco, California.

    • $1M to $10M annual revenues
    • 1-10 employees
    • $70M raised in March, 2018
    • 2 founders
    • CEO Info & Email: Available in our premium reports 🔐
    • Likely to outsource: Available in our premium reports 🔐

    Visit Website →


  247. grayscale photo of people in room


  248. Endogena Therapeutics (Less than $1M)

    Endogena Therapeutics is a biotech company that develops endogenous regenerative medicines to repair and regenerate tissues and organs. Endogena's approach has the potential of a paradigm shift to treat degenerative conditions related to ageing and genetic disorders. The company implements innovation in the field of regenerative medicine. Their science combines the latest developments in stem cell biology, AI, and expertise in small-molecule drug design to develop breakthrough treatments for degenerative diseases.

    • Less than $1M annual revenues
    • 1-10 employees
    • $8M raised in January, 2021
    • 2 founders
    • CEO Info & Email: Available in our premium reports 🔐
    • Likely to outsource: Available in our premium reports 🔐

    Visit Website →


  249. two men using computers


  250. Truust Neuroimaging ($10M to $50M)

    Their neuro-imaging products dramatically increase the resolution of existing and future neuro-imaging systems, at a fraction of the cost of equivalent hardware, and far beyond what is possible with hardware alone. Increased neuro-imaging resolution is a key enabler of new research discoveries and up-coming technologies like brain-computer interfaces, augmented cognition and artificial intelligence. Increased neuro-imaging resolution represents a leap forward in clinical diagnosis, treatment and prevention of brain-related conditions, such as epilepsy, age-related and neuro-degenerative diseases like ALS, Alzheimer’s and Parkinson’s.

    • $10M to $50M annual revenues
    • 1-10 employees
    • $0.3M raised in September, 2015
    • 2 founders
    • CEO Info & Email: Available in our premium reports 🔐
    • Likely to outsource: Available in our premium reports 🔐

    Visit Website →


  251. group of people sitting beside rectangular wooden table with laptops


  252. Ossium Health ($1M to $10M)

    Ossium is building the world's first bone marrow bank to treat blood cancers, improve organ transplantation, and repair damage from radiation.The cells of the immune system are the human body’s natural defenders against disease. At Ossium, they are developing better methods of recovering, preserving, deploying these critical cells to keep disease at bay.

    • $1M to $10M annual revenues
    • 11-50 employees
    • $10.4M raised in May, 2018
    • 3 founders
    • CEO Info & Email: Available in our premium reports 🔐
    • Likely to outsource: Available in our premium reports 🔐

    Visit Website →




  253. Silver Creek Pharmaceuticals (Less than $1M)

    Silver Creek Pharmaceuticals is a biotechnology company based in San Francisco, California.

    • Less than $1M annual revenues
    • 11-50 employees
    • $20M raised in February, 2018
    • 1 founder
    • CEO Info & Email: Available in our premium reports 🔐
    • Likely to outsource: Available in our premium reports 🔐

    Visit Website →


  254. man in black jacket sitting on chair


  255. TherOptix ($10M to $50M)

    TherOptix is a provider of novel treatment for anterior and posterior ocular indications.The company seeks to improve treatment outcomes by optimally targeting diseased tissue with effective molecules across a range of indications and molecule classes further leveraging a proprietary, minimally invasive anterior delivery platform.

    • $10M to $50M annual revenues
    • 1-10 employees
    • $1.9M raised in September, 2019
    • 2 founders
    • CEO Info & Email: Available in our premium reports 🔐
    • Likely to outsource: Available in our premium reports 🔐

    Visit Website →


  256. selective focus photography of desk lamp on table


  257. Ionetix ($1M to $10M)

    Ionetix is engaged in the development, manufacturing, and distribution of a novel class of superconducting cyclotrons for the point-of-care production of PET radioisotopes. With their significantly smaller size, lighter weight, lower power requirement, and lower price point, these systems offer significant advantages over conventional-design cyclotron technology. The company installs, operates, and manages cyclotrons producing the necessary doses of Ammonia N-13 at or near the imaging suite. Ionetix was founded in 2010 and is headquartered in

    • $1M to $10M annual revenues
    • 11-50 employees
    • $37.3M raised in December, 2018
    • 1 founder
    • CEO Info & Email: Available in our premium reports 🔐
    • Likely to outsource: Available in our premium reports 🔐

    Visit Website →


  258. people using desktop computer inside office


  259. Artemys Foods ($10M to $50M)

    Artemys Foods works on the next generation of meat alternatives by cultivating meat, instead of harvesting meat from animals. Artemys develops and executes a strategic vision for a biomanufacturing company that grows meat from animal cells, thereby empowering humanity to eat sustainable food.

    • $10M to $50M annual revenues
    • 1-10 employees
    • $0.1M raised in June, 2020
    • 2 founders
    • CEO Info & Email: Available in our premium reports 🔐
    • Likely to outsource: Available in our premium reports 🔐

    Visit Website →


  260. architectural photo of buildings during daytime


  261. AmbAgon Therapeutics ($10M to $50M)

    AmbAgon Therapeutics is a developer of cancer molecule therapeutics. The company offers research of a small molecule that augments a tumor-suppressing protein. AmbAgon Therapeutics was founded by Christian Ottmann, Lucas Brunsveld, and Michelle Arkin.

    • $10M to $50M annual revenues
    • 1-10 employees
    • $7.2M raised in July, 2020
    • 3 founders
    • CEO Info & Email: Available in our premium reports 🔐
    • Likely to outsource: Available in our premium reports 🔐

    Visit Website →


  262. people sitting in front of computer monitors


  263. IgGenix (Less than $1M)

    IgGenix is a biotechnology company, directly address food and other severe allergies by re-engineering key antibodies involved in the allergic cascade. IgGenix isolates and transforms allergen-specific IgE antibodies into IgG antibodies that are designed to alleviate and possibly prevent the allergic cascade.

    • Less than $1M annual revenues
    • 1-10 employees
    • $10M raised in August, 2020
    • 4 founders
    • CEO Info & Email: Available in our premium reports 🔐
    • Likely to outsource: Available in our premium reports 🔐

    Visit Website →


  264. people standiunmg


  265. Aligos Therapeutics ($1M to $10M)

    Aligos Therapeutics, Inc. is a clinical stage biopharmaceutical company that was founded in 2018 with the mission to become a world leader in the treatment of viral infections and liver diseases. Aligos is focused on the development of targeted antiviral therapies for chronic hepatitis B (CHB) and coronaviruses as well as leveraging its expertise in liver diseases to create targeted therapeutics for nonalcoholic steatohepatitis (NASH). Aligos’ strategy is to harness the deep expertise and decades of drug development experience its workforce has in liver disease, particularly viral hepatitis, to rapidly advance its pipeline of potentially best-in-class molecules.

    • $1M to $10M annual revenues
    • 1-10 employees
    • $125M raised in January, 2020
    • 2 founders
    • CEO Info & Email: Available in our premium reports 🔐
    • Likely to outsource: Available in our premium reports 🔐

    Visit Website →


  266. people sitting on chairs near tables during daytime


  267. Urhyme (Less than $1M)

    Urhyme is a social networking service for personal data analytics and visualization to keep focusing on self-efficiency and daily motivation. We know it is hard to focus on a goal without self-efficiency and self-motivation. The company was founded in 2015 and headquartered in California, United States.

    • Less than $1M annual revenues
    • 1-10 employees
    • $0.2M raised in January, 2016
    • 1 founder
    • CEO Info & Email: Available in our premium reports 🔐
    • Likely to outsource: Available in our premium reports 🔐

    Visit Website →


  268. two women sitting beside table using MacBooks


  269. Frontier Medicines ($1M to $10M)

    Frontier Medicines’is a developer of a chemoproteomics platform intended to further accelerate the path to drug discovery. The company's platform integrates advanced computational approaches and machine learning to discover and pharmacologically target new binding pockets on proteins, making them accessible to small-molecule drug discovery and development, enabling patients to consume breakthrough medicines that redefine the course of debilitating diseases.

    • $1M to $10M annual revenues
    • 11-50 employees
    • $67M raised in June, 2019
    • 1 founder
    • CEO Info & Email: Available in our premium reports 🔐
    • Likely to outsource: Available in our premium reports 🔐

    Visit Website →


  270. man and woman sitting at table


  271. Menten AI (Less than $1M)

    Menten AI designs new protein drugs and enzymes using quantum computers and machine learning. Proteins are large molecules that can twist into many shapes. Discovering the right shape for a protein to be a drug or a biocatalyst among almost endless possibilities is a major challenge. Menten AI solves this problem by using machine learning and quantum computing to find better starting points for discovery and further development. Quantum computing makes it possible to represent multiple states of the protein simultaneously and efficiently find the best designs. The team created the world’s first peptide designed on a quantum computer and is now working on peptide therapeutics for oncology and neurodegeneration, as well as on enzymes for industrial applications.

    • Less than $1M annual revenues
    • 1-10 employees
    • $4M raised in June, 2020
    • 3 founders
    • CEO Info & Email: Available in our premium reports 🔐
    • Likely to outsource: Available in our premium reports 🔐

    Visit Website →


  272. men sitting of chair inside room


  273. Cell Design Labs ($1M to $10M)

    Cell Design Labs is a biotherapeutics company pioneering breakthrough science to develop disruptive cell-based therapies for cancer and other devastating diseases. Cell Design Labs leverages the power of the body’s immune system to develop smart, living therapies with the capability to treat our most challenging diseases with unprecedented power, precision, safety and durability

    • $1M to $10M annual revenues
    • 11-50 employees
    • $34.4M raised in June, 2016
    • 2 founders
    • CEO Info & Email: Available in our premium reports 🔐
    • Likely to outsource: Available in our premium reports 🔐

    Visit Website →


  274. brown wooden table and chairs


  275. BioTrillion ($1M to $10M)

    We so often think of Healthcare as an industry, that we tend to forget about Healthcare as a purpose. Globally and annually, trillions of dollars are ineffectively spent on healthcare and trillions of life data points are ineffectively connected to insights about our health. There is a better way. BioTrillion is a little startup with bold ambitions to more efficatiously and scalably advance Healthcare – via Digital Biomarkers. Every human generates massive amounts of life data that will unlock novel health insights & applications. BioTrillion is developing a mobile health technology platform called BioEngine4D™ – for digitally detecting dangeous drugs, digitally detecting developing diseases, and data driven drug development – by measuring data from life, analyzing it through computational advancements in machine learning and artificial intelligence, and applying it back for life. BioTrillion, Inc. is headquartered in San Francisco, CA and is reimagining Life Sciences through the fundamental principles of many sciences. Our mission is to enable consumer smart devices to empower ordinary consumers with extraordinary health insights. Advances in technology have amplified our individual capabilities in many ways, and healthcare should be no exception. Website: www.biotrillion.com Contact: contact@biotrillion.com Jobs: https://www.biotrillion.com/opportunities Application: https://biotrillion.typeform.com/to/wSvoKI

    • $1M to $10M annual revenues
    • 1-10 employees
    • $2.3M raised in August, 2018
    • 1 founder
    • CEO Info & Email: Available in our premium reports 🔐
    • Likely to outsource: Available in our premium reports 🔐

    Visit Website →


  276. people having meeting on rectangular brown table


  277. ViaeX (Less than $1M)

    ViaeX creates biological nanofiltration systems for water and air which are 400% more efficient than current solutions and enable selective pollutant and bacteria targeting. These systems are biodegradable, low cost, and rapidly scalable to enable fast deployment in cities around the world facing serious pollution issues. Advances in nanotechnology have paved the way for innovations that can combat the 9 million annual deaths caused by water and air pollution and reduce the $1.4 trillion global economic loss due to pollution annually. At ViaeX Technologies, they are focused on developing nanofiltration solutions to provide industrial and municipal customers with energy efficient, environmentally friendly, and selective filtration systems. Their technological platform has been developed over many years of fundamental research at UC Berkeley and UC San Diego. Based on novel physical-chemistry breakthroughs they have designed a system that overcomes many disadvantages of traditional filters by utilizing the potential of nanotechnology.

    • Less than $1M annual revenues
    • 1-10 employees
    • $4M raised in May, 2017
    • 3 founders
    • CEO Info & Email: Available in our premium reports 🔐
    • Likely to outsource: Available in our premium reports 🔐

    Visit Website →


  278. people sitting beside rectangular brown table with laptops


  279. Qualio ($10M to $50M)

    Qualio is a SaaS quality management platform that helps life sciences companies become quality-driven and accelerate growth. It unites their quality team, tools, and data - helping teams building life-saving products get to market quickly and scale successfully. It was founded in 2012 and is headquartered in San Francisco, California.

    • $10M to $50M annual revenues
    • 11-50 employees
    • $11M raised in July, 2020
    • 1 founder
    • CEO Info & Email: Available in our premium reports 🔐
    • Likely to outsource: Available in our premium reports 🔐

    Visit Website →


  280. photo of industrial machines near table


  281. Better Therapeutics ($1M to $10M)

    Better Therapeutics discovers, develops and commercializes prescription digital therapeutics for the treatment of cardiovascular and metabolic diseases. We use clinically-validated, FDA-regulated software to change the behaviors that cause these diseases thereby improving quality of life, reducing the need for medications, and lowering costs. Our products deliver digital behavioral therapy that integrates neuroscience, lifestyle medicine, and explainable AI into a physician-prescribed mobile medical app, and uses patient-generated data to inform clinical decision-making and improve treatment outcomes. Our current product pipeline includes therapeutic candidates for the treatment of type 2 diabetes, hypertension, and dyslipidemia. Our founding team has started, led and exited multiple technology companies that have transformed industries and generated billions of dollars in enterprise value. The 17th Surgeon General of the US, Dr. Richard Carmona, serves as an independent board director. We were founded in 2015 and are headquartered in San Francisco, CA.

    • $1M to $10M annual revenues
    • 11-50 employees
    • $21.8M raised in December, 2015
    • 2 founders
    • CEO Info & Email: Available in our premium reports 🔐
    • Likely to outsource: Available in our premium reports 🔐

    Visit Website →


  282. people sitting on black chairs


  283. Ivy Natal ($10M to $50M)

    Ivy Natal develops a process to create human egg cells from skin samples as a treatment for most cases of infertility.

    • $10M to $50M annual revenues
    • 1-10 employees
    • $0.3M raised in April, 2020
    • 2 founders
    • CEO Info & Email: Available in our premium reports 🔐
    • Likely to outsource: Available in our premium reports 🔐

    Visit Website →


  284. man in gray sweatshirt sitting on chair in front of iMac


  285. Grace Science (Less than $1M)

    Grace Science is a developer of small molecule inhibitors of NGLY1 to treat various forms of cancer.

    • Less than $1M annual revenues
    • 1-10 employees
    • $7M raised in February, 2017
    • 1 founder
    • CEO Info & Email: Available in our premium reports 🔐
    • Likely to outsource: Available in our premium reports 🔐

    Visit Website →


  286. men using computers


  287. Profusa ($1M to $10M)

    Profusa, Inc. operates in the health care sector. It is dedicated to the development of a new generation of biointegrated sensors that empowers the individual with the ability to monitor their unique body chemistry in unprecedented ways to transform the management of personal health and disease. The company was incorporated in 2009 and is based in Cupertino, California.

    • $1M to $10M annual revenues
    • 51-100 employees
    • $45M raised in August, 2018
    • 3 founders
    • CEO Info & Email: Available in our premium reports 🔐
    • Likely to outsource: Available in our premium reports 🔐

    Visit Website →




  288. 20n (Less than $1M)

    At 20n, They use algorithms to engineer microbes. Specifically, their algorithms engineer microbes to make chemicals. Like yeast produces alcohol during beer brewing, their engineered microbes will produce chemicals with therapeutic health and industrial biotech applications. The best illustration of this DARPA-backed technology is the bacteria They engineered to produce Paracetamol (also known as acetaminophen, and sold under the brand name Tylenol). Aside from this bacteria, there is no known natural way of producing acetaminophen. They are building data mining technology that will allow us to enable the bioproduction of a whole spectrum of valuable molecules. Below is the map of every chemical that can be made biologically, as discovered by 20n's algorithms.

    • Less than $1M annual revenues
    • 1-10 employees
    • $2.1M raised in May, 2015
    • 2 founders
    • CEO Info & Email: Available in our premium reports 🔐
    • Likely to outsource: Available in our premium reports 🔐

    Visit Website →


  289. people sitting and using laptops


  290. Napo Pharmaceuticals ($1M to $10M)

    Napo Pharmaceuticals, Inc. develops and commercializes proprietary pharmaceuticals for international markets. It offers Crofelemer for gastrointestinal indications, including chronic diarrhea in persons living with HIV/AIDS; and NP-500, a product for insulin-resistant diseases. The company also provides CRO-IBS for diarrhea-predominant IBS; CRO-HIV for AIDS-related diarrhea; CRO-ID for acute infectious diarrhea; and CRO-PED for pediatric diarrhea. It offers its products for D-IBS, HIV, acute-cholera, and pediatric markets. The company was founded in 2001 and is based in San Francisco, California. It has a subsidiary location in Mumbai, India.

    • $1M to $10M annual revenues
    • 11-50 employees
    • $2M raised in January, 2017
    • 1 founder
    • CEO Info & Email: Available in our premium reports 🔐
    • Likely to outsource: Available in our premium reports 🔐

    Visit Website →


  291. rolling armchair beside table


  292. JointechLabs (Less than $1M)

    JointechLabs is a developer of Mini-Stem System and 3D Cell Encapsulation of ADSC for improved access to cell therapies and its increased efficacy. JointechLabs mission is to simplify accessibility to cell based therapies for doctors and patients by providing cost-effective, immediate, on-site access to high-quality optimized adipose-derived stromal cells (ADSC) for improved efficacy of cell-based therapies.

    • Less than $1M annual revenues
    • 1-10 employees
    • $0.3M raised in April, 2018
    • 3 founders
    • CEO Info & Email: Available in our premium reports 🔐
    • Likely to outsource: Available in our premium reports 🔐

    Visit Website →


  293. rectangular brown wooden table with chair lot inside building


  294. Actym ($1M to $10M)

    Actym is a biotechnology company that focuses on developing an immuno-oncology platform. It specializes in the fields of medical device, manufacturing, and distribution. It focuses on a novel tumor-targeting, systemically-delivered STING pathway agonist that demonstrates robust anti-tumor. It was founded in 2017 and headquartered in San Francisco, California.

    • $1M to $10M annual revenues
    • 11-50 employees
    • $34M raised in April, 2020
    • 2 founders
    • CEO Info & Email: Available in our premium reports 🔐
    • Likely to outsource: Available in our premium reports 🔐

    Visit Website →


  295. three women sitting around table using laptops


  296. Asher Bio ($10M to $50M)

    Asher Bio is an information technology company that specializes in the fields of CFO Office transformation, profitability, and cost management. It focuses on building and developing better immunotherapy for cancer. The company was founded in 2019 and headquartered in San Francisco, California.

    • $10M to $50M annual revenues
    • 1-10 employees
    • $0.2M raised in August, 2019
    • 1 founder
    • CEO Info & Email: Available in our premium reports 🔐
    • Likely to outsource: Available in our premium reports 🔐

    Visit Website →


  297. brown and white table and chairs


  298. Healthiest You ($10M to $50M)

    HealthiestYou is an industry leader in eHealth user engagement and was recently ranked #846 on the 2015 Inc. 5000 list of the nation’s fastest-growing private companies. By directing medical claims out of traditional insurance plans, HealthiestYou serves as an accessible and affordable complement to primary care, saving time, money, worry, and hassle for companies and their employees.

    • $10M to $50M annual revenues
    • 11-50 employees
    • $30M raised in November, 2015
    • 1 founder
    • CEO Info & Email: Available in our premium reports 🔐
    • Likely to outsource: Available in our premium reports 🔐

    Visit Website →


  299. grey wooden table and black leather rolling chairs


  300. Datavant ($1M to $10M)

    Datavant is a developer of a healthcare data platform dedicated to assisting in protecting, matching, and sharing health data. The platform that the company offers organizes healthcare data for use in clinical trial decision-making. Its focus is on the employment of artificial intelligence to improve the clinical trial process and to improve the design and interpretation of clinical trials, helping pharmaceutical companies to manage the privacy, security, compliance, and trust required to enable safe data sharing. Travis May established Datavant in San Francisco, California in 2017.

    • $1M to $10M annual revenues
    • 51-100 employees
    • $40M raised in October, 2020
    • 1 founder
    • CEO Info & Email: Available in our premium reports 🔐
    • Likely to outsource: Available in our premium reports 🔐

    Visit Website →


  301. tennis table in room


  302. goBalto ($10M to $50M)

    GoBalto is a software platform that develops cloud-based solutions for drug trial sponsors and clinical research organizations. Its products offer drug trial sponsors and clinical research organizations the fastest, easiest possible way to start clinical studies on the web. The company was founded in 2008 and headquartered in San Francisco, California.

    • $10M to $50M annual revenues
    • 11-50 employees
    • $12.1M raised in January, 2015
    • 1 founder
    • CEO Info & Email: Available in our premium reports 🔐
    • Likely to outsource: Available in our premium reports 🔐

    Visit Website →


  303. rectangular brown wooden table


  304. MYI Diagnostics (Less than $1M)

    MYI Diagnostics is a biomedical research company that specializes in multiplexed proteomic profiling for precision medicine. MYI Diagnostics conducts confidential research in order to replace many of the targeted diagnostics for individual cancers, infectious diseases, metabolic conditions, and other rare or common disorders. The company also generates actionable individualized information to streamline clinical intervention strategies. MYI Diagnostics was founded by, Nicholas J. Schork, Devon Cayer, and Kristopher L. Nazor in 2015. The company is based in San Diego, California.

    • Less than $1M annual revenues
    • 1-10 employees
    • $0.3M raised in September, 2015
    • 4 founders
    • CEO Info & Email: Available in our premium reports 🔐
    • Likely to outsource: Available in our premium reports 🔐

    Visit Website →


  305. grayscale photo of people in room


  306. Serenus Biotherapeutics ($1M to $10M)

    Serenus Biotherapeutics is a privately held specialty biopharmaceutical company that specializes in late-stage drug development, in-licensing, registering, and commercializing therapies approved in the United States, Europe, and Japan to address unmet medical needs with high regional prevalence in the African market.

    • $1M to $10M annual revenues
    • 11-50 employees
    • $43M raised in March, 2015
    • 1 founder
    • CEO Info & Email: Available in our premium reports 🔐
    • Likely to outsource: Available in our premium reports 🔐

    Visit Website →


  307. two men using computers


  308. Vir Biotechnology ($1M to $10M)

    Vir Biotechnology is a clinical-stage immunology company developing therapeutic products to treat and prevent serious infectious diseases. The company brings together cutting-edge innovations with scientific expertise and management. It seeks to take a new approach, using breakthroughs in immune programming to manipulate pathogen-host interactions. Vir Biotechnology also focused on combining immunologic insights with cutting-edge technologies to treat and prevent serious infectious diseases. The company four current technology platforms are designed to, either individually or in combination, stimulate and enhance the immune system by exploiting critical observations of natural immune processes. Their vision is that one day, diseases like hepatitis B, influenza A, HIV, and tuberculosis become a thing of the past.

    • $1M to $10M annual revenues
    • 101-250 employees
    • $250M raised in April, 2020
    • 2 founders
    • CEO Info & Email: Available in our premium reports 🔐
    • Likely to outsource: Available in our premium reports 🔐

    Visit Website →


  309. group of people sitting beside rectangular wooden table with laptops


  310. Shasqi (Less than $1M)

    Shasqi develops cancer treatment intended to use bio-orthogonal chemistry for localized drug delivery. Its treatment permits delivery of more than one drug to the tumor with fewer side effects, enabling physicians to treat their patients in an enhanced way.

    • Less than $1M annual revenues
    • 1-10 employees
    • $10M raised in October, 2019
    • 1 founder
    • CEO Info & Email: Available in our premium reports 🔐
    • Likely to outsource: Available in our premium reports 🔐

    Visit Website →




  311. Meissa Vaccines (Less than $1M)

    Meissa Vaccines is a start-up pharmaceutical development company focused on the in-licensing and advancement of vaccines for respiratory syncytial virus (RSV, the largest unmet respiratory medical need in pediatrics) and rhinovirus (leading cause of infectious disease worldwide). Their passion is child health, but our vaccine programs have the potential to benefit multiple age groups directly and indirectly. Successful vaccines for respiratory syncytial virus and rhinovirus would have widespread benefits for society and families. These include reducing the burden of acute lower respiratory tract disease, reducing colds, reducing acute asthma exacerbations caused by these viruses, and alleviating missed school and work.

    • Less than $1M annual revenues
    • 11-50 employees
    • $30M raised in September, 2019
    • 2 founders
    • CEO Info & Email: Available in our premium reports 🔐
    • Likely to outsource: Available in our premium reports 🔐

    Visit Website →


  312. man in black jacket sitting on chair


  313. Codiak Biosciences ($10M to $50M)

    Codiak is a clinical-stage biopharmaceutical company focused on pioneering the development of exosome-based therapeutics, a new class of medicines with the potential to transform the treatment of a wide spectrum of diseases with high unmet medical need. By leveraging the biology of exosomes as natural intercellular transfer mechanisms, Codiak has developed its proprietary engEx Platform to expand upon the innate properties of exosomes to design, engineer and manufacture novel exosome therapeutic candidates. Codiak has utilized its engEx Platform to generate a deep pipeline of engineered exosomes aimed at treating a broad range of disease areas, spanning oncology, neuro-oncology, neurology, neuromuscular disease and infectious disease.

    • $10M to $50M annual revenues
    • 101-250 employees
    • $57.8M raised in February, 2021
    • 2 founders
    • CEO Info & Email: Available in our premium reports 🔐
    • Likely to outsource: Available in our premium reports 🔐

    Visit Website →


  314. selective focus photography of desk lamp on table


  315. Brex ($10M to $50M)

    Brex is reimagining financial systems so every growing company can realize their full potential. With the financial OS, new customers can get up and running in minutes with corporate credit cards and cash management in a single, strategic account. Plus, companies save hours every month with built-in tools and integrations to track spend, and earn points on every card purchase. Launched in 2018, Brex has raised $315M in equity funding alongside $350M in debt financing, and is backed by the likes of Y Combinator Continuity, Kleiner Perkins, and the founders of PayPal. Headquartered in San Francisco, Brex also has offices in Vancouver, B.C. and the Salt Lake valley. Brex was founded by Henrique Dubugras and Pedro Franceschi, two engineers who previously founded Pagar.me, one of the largest payment processors in Brazil with over $1.5 billion in GMV.

    • $10M to $50M annual revenues
    • 251-500 employees
    • $150M raised in May, 2020
    • 2 founders
    • CEO Info & Email: Available in our premium reports 🔐
    • Likely to outsource: Available in our premium reports 🔐

    Visit Website →


  316. people using desktop computer inside office


  317. BlackThorn Therapeutics ($1M to $10M)

    BlackThorn Therapeutics operator of a clinical-stage biopharmaceutical company intended to develop precision medicine for disorders of the central nervous system (CNS) based on advances in computational and clinical neuroscience. The company leverages a deep understanding of brain and behavior relationships that seeks to overcome historic challenges in drug discovery and development by targeting dysfunctional brain circuits. Its proprietary computational platform, the company seeks to identify novel targets, small molecule drug candidates and biologically-based patient subgroups most likely to respond to treatment.

    • $1M to $10M annual revenues
    • 11-50 employees
    • $76M raised in June, 2019
    • 2 founders
    • CEO Info & Email: Available in our premium reports 🔐
    • Likely to outsource: Available in our premium reports 🔐

    Visit Website →


  318. architectural photo of buildings during daytime


  319. ProLynx ($10M to $50M)

    ProLynx develops advanced linker technologies and a facile with a transformative platform for controlled release of therapeutics from circulating and fixed macromolecular conjugates. The company's technology is dedicated to the development of linker systems to enable predictable and controllable half-extension of drugs. ProLynx was founded in 2009 by Daniel V. Santi and Gary W. Ashley and is based in San Francisco, California.

    • $10M to $50M annual revenues
    • 1-10 employees
    • $0.1M raised in August, 2020
    • 2 founders
    • CEO Info & Email: Available in our premium reports 🔐
    • Likely to outsource: Available in our premium reports 🔐

    Visit Website →


  320. people sitting in front of computer monitors


  321. Ranomics ($1M to $10M)

    Ranomics focuses on providing individuals with health risk predictions according to their genetic data. Ranomics offers RanomicsDB and Ranomics API. RanomicsDB is a query interface with VCF support. Ranomics API is a developer-friendly API that enables variant interpretation software companies to integrate data to enhance their existing pipeline. Ranomics was founded in 2015 by Leo Wan and Cathy Tie. And it is based in San Francisco, California.

    • $1M to $10M annual revenues
    • 1-10 employees
    • $1.2M raised in September, 2016
    • 2 founders
    • CEO Info & Email: Available in our premium reports 🔐
    • Likely to outsource: Available in our premium reports 🔐

    Visit Website →


  322. people standiunmg


  323. Soley Therapeutics (Less than $1M)

    Soley Therapeutics combines AI with molecular and cellular response detection for developing new efficacious drugs, using image acquisition-based approaches. Soley Therapeutics has taken an orthogonal approach to discover new drugs by developing a technology platform to measure how cells respond multi-dimensionally in response to drugs. We have developed a novel platform for high-content phenotypic drug screening, where the drug effect on a cell can be visualized via molecular-microscopic images and analyzed by using sophisticated AI tools.

    • Less than $1M annual revenues
    • 1-10 employees
    • $20M raised in December, 2020
    • 2 founders
    • CEO Info & Email: Available in our premium reports 🔐
    • Likely to outsource: Available in our premium reports 🔐

    Visit Website →


  324. people sitting on chairs near tables during daytime


  325. SilviaTerra ($1M to $10M)

    SilviaTerra's vision is that our planet's forests would be fully understood and fairly valued. To that end, we believe that measurements make markets. So we use our high-resolution forest data to underpin markets in carbon offsets, biodiversity, fire risk reduction, and more.

    • $1M to $10M annual revenues
    • 11-50 employees
    • $4.4M raised in December, 2020
    • 2 founders
    • CEO Info & Email: Available in our premium reports 🔐
    • Likely to outsource: Available in our premium reports 🔐

    Visit Website →


  326. two women sitting beside table using MacBooks


  327. Circle Pharma ($1M to $10M)

    Circle Pharma is an early stage biotechnology company applying proprietary computational design algorithms and innovative chemistry to develop cell permeable macrocycle peptide therapeutics against important clinical targets. It does this through an iterative, rational design process that deploys large virtual libraries of conformationally diverse macrocycle scaffolds selected for inherent permeability. The company was founded by Prof. Matt Jacobson, Ph.D. (U.C. San Francisco) and Prof. Scott Lokey, Ph.D. (U.C. Santa Cruz) and is headed by David J. Earp, J.D., Ph.D.

    • $1M to $10M annual revenues
    • 11-50 employees
    • $45M raised in March, 2020
    • 2 founders
    • CEO Info & Email: Available in our premium reports 🔐
    • Likely to outsource: Available in our premium reports 🔐

    Visit Website →


  328. man and woman sitting at table


  329. Enveda Biosciences ($10M to $50M)

    Enveda Biosciences is a biotechnology company building new medicines from plants. It harnesses the complexity of the natural world to tackle today’s biggest healthcare challenges. With the help of the advancements in knowledge graphs, machine learning, and metabolomics, they discover the next generation of small molecules. Its technologies systematize the discovery of small molecules and novel targets for complex diseases. By probing novel chemical space and mechanisms of action, they are breaking the status quo for challenging diseases with a need for effective treatments, such as fibrosis or neurodegeneration. Enveda, launched in 2019, is based in San Francisco, California.

    • $10M to $50M annual revenues
    • 11-50 employees
    • $4.9M raised in August, 2020
    • 1 founder
    • CEO Info & Email: Available in our premium reports 🔐
    • Likely to outsource: Available in our premium reports 🔐

    Visit Website →


  330. men sitting of chair inside room


  331. Concentric Analgesics (Less than $1M)

    Concentric Analgesics is a biotechnology company focused on developing non-opioid therapeutics for the management of acute and chronic pain. The company is driven by a mission is to dramatically improve the lives of patients by developing breakthrough non-opioid pain therapeutics that address significant medical needs. Concentric Analgesics was founded in 2014 and is headquartered in San Francisco, California.

    • Less than $1M annual revenues
    • 11-50 employees
    • $77.1M raised in May, 2019
    • 2 founders
    • CEO Info & Email: Available in our premium reports 🔐
    • Likely to outsource: Available in our premium reports 🔐

    Visit Website →


  332. brown wooden table and chairs


  333. Xalud Therapeutics (Less than $1M)

    Xalud Therapeutics is a biotech company that develops therapies for the treatment of neuro-inflammatory diseases. It offers a gene therapy platform that addresses chronic pain. The lead product candidate, XT-150 is in two P2 clinical studies for the treatment of Osteoarthritis Pain. Xalud is a portfolio company of PBM Capital Group. The company was established in 2009 and is based in San Francisco, California, United States.

    • Less than $1M annual revenues
    • 1-10 employees
    • $5M raised in March, 2020
    • 2 founders
    • CEO Info & Email: Available in our premium reports 🔐
    • Likely to outsource: Available in our premium reports 🔐

    Visit Website →


  334. people having meeting on rectangular brown table


  335. Phylagen ($1M to $10M)

    Phylagen, Inc. is a data analytics company leveraging artificial intelligence to harness the vast, unseen world of microbes. Phylagen uses DNA sequencing and machine learning to turn the largest untapped dataset on the planet, the environmental microbiome, into insights for customers across numerous industries.

    • $1M to $10M annual revenues
    • 11-50 employees
    • $14M raised in February, 2019
    • 2 founders
    • CEO Info & Email: Available in our premium reports 🔐
    • Likely to outsource: Available in our premium reports 🔐

    Visit Website →


  336. people sitting beside rectangular brown table with laptops


  337. Pendulum Therapeutics (Less than $1M)

    The pendulum is the microbial company to apply the discoveries of high-resolution, long-read DNA sequencing to the development of microbiome interventions targeting specific diseases. With a team of accomplished scientists, clinicians, engineers and innovators committed to Its mission of making millions healthier through microbiome-targeted medical probiotics.

    • Less than $1M annual revenues
    • 11-50 employees
    • $35M raised in May, 2019
    • 3 founders
    • CEO Info & Email: Available in our premium reports 🔐
    • Likely to outsource: Available in our premium reports 🔐

    Visit Website →


  338. photo of industrial machines near table


  339. Virus Geeks Inc. (Less than $1M)

    Virus Geeks is a data-driven BioHealth technology company that develops health-centric initiatives to improve the quality of life through strategic partnerships across healthcare & biotechnology sectors. We help communities gain access to COVID-19 testing and related healthcare benefits.

    • Less than $1M annual revenues
    • 11-50 employees
    • $0.1M raised in July, 2020
    • 2 founders
    • CEO Info & Email: Available in our premium reports 🔐
    • Likely to outsource: Available in our premium reports 🔐

    Visit Website →


  340. people sitting on black chairs